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Incorporation of chemical probes into proteins is a powerful way to 
elucidate biological processes and to engineer novel function. This thesis 
describes the ligation of synthetic molecules to target proteins in an 
intracellular environment, and the use of semi-synthetic proteins for whole 
animal studies. 
In the first approach a cellular protein is genetically tagged with one 
half of a split-intein. The complementary half is linked in vitro to the 
synthetic probe and this fusion is delivered into cells using a transduction 
peptide. Association of the intein halves in the cytosol triggers protein trans-
splicing, resulting in the ligation of the probe to the target protein through 
a peptide bond. This process is specific and applicable to cytosolic and 
integral membrane proteins. The technology should allow cellular proteins to 
be elaborated with a variety of abiotic probes. 
In the second approach a sequential expressed protein ligation was 
used to link three fragments: a targeting protein, an affinity tag, and an 
imaging moiety. Specifically, vascular endothelial growth factor (VEGF) was 
ligated with a 6xHis tag and a synthetic high affinity "°Tc chelator. 
Following protein semi-synthesis, the "°Tc was incorporated into the chelator 
and the "-To-labeled protein was injected into mice bearing a tumor. The 
semi-synthetic VEGF localized onto the vascularized tumor and allowed it to 
be imaged with a Y camera. The strategy developed is modular, permitting 
the use of multiple chemical moieties, purification methods, and targeting 
proteins. This methodology could be used to provide insights into biological 
processes in normal development and homeostasis, as well as during 
pathogenic events such as cancers. 
Chapter 1: Introduction. 
Proteins account for more then 5 0 % of the dry weight of most cells 
and they are viewed as the basic machinery inside the cell. They are 
involved in structural support, defense against foreign agents, acceleration of 
chemical reactions (enzymatic activity), signaling, movement and the storage 
and transport of substances within the cell.85 Historically, proteins have 
been studied using biochemistry, a discipline that distinguishes itself by the 
first act of its practitioners: converting cells into a soup. Studies of the 
molecules purified from this soup serve to define the spectrum of possible 
functions that proteins could carry out within the living cell. Biochemistry 
remains a vibrant field but the reductionism at its heart creates limitations. 
Proteins are in an unnatural environment and under such artificial 
conditions, biochemists have to continually question the relevance of their in 
vitro systems to the cellular environment. 
"A clever engineer can make a vacuum cleaner from the wreck 
of an automobile, but this does not show that cars contain 
vacuum cleaners." Green."''5 
Geography, movement and chemistry are what provide proteins with 
their extraordinary capability to regulate processes in living cells, such that 
only in vivo experiments can determine where, within the spectrum of 
possible functions, the actual biological functions of proteins reside. Thus, 
manipulating proteins in vivo, in the context of relevant physiochemical 
conditions, is a necessary approach to complement biochemistry. 
Classical genetics with techniques such as mutagenesis, over-expression, 
knock-out, conditional alleles and others,66 has proven to be a powerful tool 
for the study of proteins inside cells. Recently, these approaches have been 
complemented by the discovery of fluorescent proteins. 
Green Fluorescent Proteins. 
The green fluorescent protein, isolated from Aequorea victoria, is a |3-
barrel-shaped protein that contains an amino acid triplet (Ser-Tyr-Gly) which 
undergoes a chemical rearrangement to form a fluorophore.69 GFP is most 
celebrated for its ability to act as a genetic fluorescent marker, being directly 
visible in the living cell and requiring no fixation, substrates or co-
enzymes.137 This characteristic has allowed for visualizing the location and 
trafficking of proteins in vivo,1311 labeling of many sub-cellular structures120 
and discovery of genes whose products have a specific intracellular location.63 
Because of this success, both random and rational mutagenesis have been 
used to create G F P variants with new colors, improved folding, varied 
extinction coefficients and quantum yields137 which, together with orthologues 
fluorescent proteins such as the sea coral protein DsRed,11 98 have increased 
the breadth of genetic fluorescent markers. 
New GFPs can now report on the chemical environment of a protein 
thanks to their engineered sensitivity to acidity,82 89 or concentration of ions 
such as Cl,73 Ca2*101 and Zn2*.10 Importantly, the availability of fluorescent 
proteins with diverse colors permits the study of protein-protein interactions 
through the use of fluorescence resonance energy transfer (FRET).94 101 
One of the most recent development is a fluorescent protein whose 
spectral properties change with time. The "fluorescent timer" protein was 
generated by random mutagenesis of the red fluorescent protein DsRed.130 
This protein initially produces a green-emitting fluorophore (similar to that of 
GFP), which over time undergoes an oxygen-dependent autocatalytic reaction 
to create a red-emitting fluorophore. The rate of color conversion is 
independent of protein concentration and can be used to trace time-
dependent activation and down-regulation of the promoters of target 
proteins.130 
Although powerful, there are limitations to the use of GFP-fusion 
reporters. These include the potential perturbation to the protein of interest 
(due to GFPs' size of 238 amino acids), significant delay between protein 
synthesis and the development of fluorescence (1 hour), limited points of 
attachment, a complex photoisomerization and a small spectral range.137 The 
introduction of unnatural moieties into proteins in vivo could overcome some 
of these limitations and open the possibility of exploiting the orthogonality 
and selectivity that chemistry has to offer. A unique probe on a protein of 
interest allows it to be easily identified from a multitude of similar species, 
and permits specific reactions between proteins to take place. 
Chemical modification of proteins in vivo. 
Chemical modification of proteins in living cells originally involved the 
non-specific modification of membrane proteins with fluorescent molecules 
that were covalently attached to these proteins through their side chain 
amino or sulfhydryl groups. Initially such experiments were performed to 
determine what parts of the membrane proteins were extra-cellular,40 but 
later they permitted the study of protein diffusion constants in the plasma 
membrane using fluorescent recovery after photo-bleaching (FRAP).6 
Selective Pressure Incorporation. 
More recently, an in vivo method termed selective pressure 
incorporation18 was developed to exploit the promiscuity of wild-type bacterial 
synthetases. Inducing expression of a recombinant protein in an auxotrophic 
strain grown in minimal media with an unnatural amino acid analog, results 
in the production of the protein containing this moiety. In general this 
method is simple to carry out, and can provide large quantities of 
engineered proteins. However, major limitations include the replacement of 
all sites corresponding to a particular natural amino acid throughout the 
protein, the variation in the extent of incorporation of the natural and 
unnatural amino acid, the toxicity of some analogues and the use of only 
close structural analogs of the common amino acids. Moreover, to date it 
has been applicable only to bacteria. 
Unnatural Amino Acid Incorporation Through Nonsense Suppression. 
Many of the limitations of selective pressure incorporation were by-
passed with the creation of unnatural amino acid incorporation through 
nonsense suppression.106 This technique uses a suppressor transfer RNA, 
chemically acylated with an unnatural amino acid, that is inserted into 
proteins in response to an amber stop codon. This new technology was 
introduced into an in vivo setting using Xenopus oocytes for protein 
synthesis107 (Figure 1.1). 
Nonsense suppression methodology has permitted in vitro and in some 
cases, in vivo analysis of structure-function relationships,33 41 incorporation of 
biophysical probes,32 78 incorporation of photo-reactive side chains and 
"unnatural arr..r.o£tid 
chonucaltv apperded 
O V n H w a inputs- no" 
Figure 1.1. General outline for the incorporation of unnatural amino 
acids through nonsense suppression into proteins in vivo. ® The gene 
of the protein is cloned with a "stop" codon at the site of interest. 
© A tRNA with the appropriate anti-codon and unnatural amino 
acid (*) is synthesized. ® Both are co-injected into a cell, most 
commonly an oocyte. © The cell produces the protein with the 
unnatural amino acid incorporated, and in the case of ion channels, 
the protein is transported to the cell surface © where it can be 
studied by electrophysiology. 
backbone mutations.34 83 Almost 100 unnatural amino acids have been 
integrated into proteins, but the technique remains challenging. Non-sense 
suppression requires stoichiometric amounts of the amino acylated tRNA 
(which is difficult to synthesize), the suppression efficiency is imperfect, the 
yields are poor and the in vivo system used has to be amicable to the 
methodology (which requires injection of both the tRNA and mRNA).42 
The latter draw-back has impeded the study of a protein within its natural 
environment (e.g. a mammalian protein in mammalian cells). However, in a 
monumental achievement, the Schultz group has made progress towards 
overcoming this limitation, by expanding the genetic code of Escherichia coli 
(E. coli).145 Three additional and orthogonal components for the protein 
biosynthetic machinery were incorporated into the bacteria: a novel tRNA-
codon pair, an aminoacyl-tRNA synthetase, and an amino acid. This new 
set of components did not cross talk with the natural machinery of E. coli, 
and it had a fidelity greater then 99% when incorporating the synthetic 
amino acid O-methyl-L-tyrosine into proteins in response to an amber 
nonsense codon.145 Since this first report, a series of unnatural amino acids 
have been incorporated into the genetic code of E. coli: O-allyl-jL-tyrosine,159 
p-azido-L-phenylalanine,25 L-3-(2-naphthyl)alanine146 and p-benzoyl-L 
phenylalanine.24 The latter was incorporated into the dimeric protein 
glutathione S-transferase (GST) and efficient cross-linking (>50%) of the 
protein subunits resulted upon irradiation of the bacteria. Such results start 
to shed light on the possibilities that could emerge when increasing the 
repertoire of functional groups that can be introduced in vivo. Although, 
nonsense suppression has made great advances, it is still unavailable in 
mammalian cells, and is restricted to the use of only two redundant stop 
codons. 
> * w 
Figure 1.2. Structure of FlAsH-EDT2. The strucmre highlighted in 
orange attaches to proteins tagged with the tetra-cysteine motif. 
FlAsH 
An alternative way to attach unnatural chemical moieties onto proteins 
was recently developed.65 A small membrane permeable ligand FlAsH (4', 5'-
bis(l,3,2-dithioarsolan-2-yl) fluorescein) (Figure 1.2) that binds the four 
cysteines in the sequence CysCysXxxXxxCysCys (where Xxx is any amino 
acids except cysteine) was developed.65 The small polypeptide to which 
FlAsH binds can be incorporated into proteins. 
FlAsH-EDT: (1,2-ethanedithiol) is practically non-fluorescent becoming 
over 50,000 times more fluorescent upon exchanging the E D T moieties for 
the tetra-cysteine sequence. This polypeptide is believed to be in a (3-hairpin 
conformation1 and the rigid spacing of the two arsenates in FlAsH enables it 
to bind with high affinity and specificity to the motif introduced in target 
proteins. Addition of micro-molar levels of 1,2-dithiols, such as E D T , can 
minimize FlAsH toxicity and nonspecific labeling, while milli-molar 
concentrations can strip FlAsH off the target proteins. The small size of the 
genetic tag (6-10 amino acids) and relative ease of the synthesis of FlAsH 
has encouraged the synthesis of new derivatives with different properties. To 
date FlAsH has been modified to have red and blue emissions, photosensitize 
the polymerization of diaminobenzidine (to produce a localize precipitate 
useful for electron microscopy) and be membrane impermeable.1 105 FlAsH 
can also survive analysis of protein by SDS-PAGE, can serve as a protein 
purification tool analogous to a His-tag1 132 and the conformational rigidity 
the FlAsH-peptide adducts should make them ideal for anisotropy studies.1 
Recently, another methodology to chemically modify proteins in vivo was 
reported. In this strategy, covalent labeling with a small molecule is 
achieved through the use of an engineered human DNA repair protein O6-
alkylguanine-DNA alkyltransferase (hAGT), which irreversibly transfers the 
alkyl group from its substrate (O'-alkylguanine-DNA) to one of its cysteines. 
The substrate specificity of hAGT was reduced, allowing the ligation of 
unnatural alkyl groups onto hAGT fusion proteins.79 
The appeal of all these methodologies is the ability to incorporate 
non-genetic coded molecules into proteins in vivo, maximizing chemically 
favorable properties and minimizing possible disruption in normal protein 
behavior. A novel approach in which a synthetic molecule is ligated to a 
protein (i.e. semi-synthesis) inside living cells could increase the diversity of 
10 
chemical modifications for probing cellular proteins and should complement 
methods already in existence. The bases for such an approach are protein 
splicing and protein transduction domain (PTD) peptides. 
Protein Splicing. 
Protein splicing is an autocatalytic, post-translational process in which 
an intervening sequence, the intein, is removed from a host protein, the 
extein.115 The first intein was discovered in 1990 as a "spacer" within the 
Saccharomyces cerevisiae vacuolar ATPase (See VMA) gene that was absent in 
other VMA homologs.70 76 127 Since then, over 100 putative inteins have 
been identified and cataloged in InBase, the on-line intein registry and 
database (http://www.neb.com/neb/inteins.html).114 Formation of a native 
peptide bond between the ligated exteins is a key distinguishing feature of 











Figure 1.3. General layout of an intein. Mini-inteins have a small 
linker region instead of the endonuclease. Conserved residues are 
shown below in bold. The intein splicing regions (blue boxes) form 
a single domain that mediates protein splicing. 
11 
have been experimentally shown to splice, while the majority have been 
found by homology searches of whole genome sequences (Figure 1.3).114 116 
The majority of inteins are bi-functional proteins that also encode homing 
endonuclease signature motifs. Homing endonucleases were originally shown 
to initiate mobility (or homing) of intron genes into sites in homologous 
genes by creating double-stranded breaks at the homing site.43 60 Several 
inteins have demonstrated endonuclease activity and the See VMA intein 
gene has been shown to be mobile in yeast.61 Biochemical analysis indicates 
that splicing and endonuclease active sites reside in different regions of the 
intein.71 This has been further established with the crystal structure of the 
See. VMA intein, which shows separately folded sub domains (Figure 1.4).117 
12 
Inteins are present in unicellular organisms from all 3 phylogenetic 
domains: Archaea, Eukarya and Eubacteria. The absence of inteins in 
multicellular organisms may be limited by the inability of mobile intein genes 
to invade germ line cells. Although the role of inteins in early evolution is 
unknown, several groups have suggested that they are selfish DNA elements, 
or could be involved in enzyme evolution by peptide or domain ligation and 
shuffling.113 It has also been proposed that inteins could control maturation 
of the protein wherein they reside,118 however this is unlikely, as splicing is 
rapid under physiological conditions, and precursors cannot be isolated 
organisms that have inteins. 
in 
Figure 1.4. Crystal structure of See. V M A . The endonuclease is 
represented in red, and the intein splicing regions in blue (see also 
Figure 1.3 - note, in Figure 1.3 the endonuclease is presented in 
black). 
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The standard protein splicing mechanism was first defined using the 
Psp-GBD Pol intein71 154 and was later confirmed with the See VMA 
intein.2829 Protein splicing requires four nucleophilic displacements mediated 
by three splice junction residues (Figure 1.5). The standard protein splicing 
reaction begins when the Ser or Cys at the intein amino-terminus undergoes 
an acyl rearrangement, replacing the amino-terminal splice junction peptide 
bond with an CC-(thio)-ester bond (Figure 1.5 ®). In the second step, a 
trans-esterification reaction occurs, moving the N-extein from the side-chain of 
the first residue in the intein to the side chain of the first residue in the 
C-extein, which is always a Ser, Thr or Cys. This step results in ligation of 
:oon 
X-»N acylshiftŶ  
COOH 
Asn cyclization 
Figure 1.5. Standard protein splicing mechanism. "X" represents the 
oxygen or sulfur atom in Ser, Thr or Cys and the steps are 
explained in the text. The succinimide ring may be hydrolyzed to 
reform Asn or isoasparagine. The N-terminal extein, C-terminal 
extein and the intein are shown in green, red and blue respectively. 
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the exteins and formation of a branched protein intermediate (Figure 1.5 © ) . 
The intein is cleaved away from this intermediate when cyclization of the 
intein carboxy-terminal Asn breaks the adjacent peptide bond at the carboxy-
terminal splice junction (Figure 1.5 ®). In the absence of the intein, a 
spontaneous rearrangement of the (X-(thio)-ester linkage between the exteins 
occurs, resulting in the formation of the more stable peptide bond (Figure 
1.5 ©). No cofactors or exogenous proteins are required for splicing 
activity. An alternative mechanism for protein splicing has also been found 
for three families of inteins that begin with Ala. In this non-canonical 
pathway the C-extein nucleophile attacks the peptide bond at the N-terminal 
splice junction directly.117 153 
Inteins function like regular enzymes, requiring facilitating groups 
positioned in three dimensional space to activate nucleophiles and 
electrophilic centers. However, unlike normal enzymes they only act on a 
single substrate, the precursor in which they exist. This is further 
highlighted when the precursor is split and splicing occurs in trans (see 
below), unequal molar ratios of fragments result in the accumulation of the 
fragment in excess and not in turnover (the limiting fragment does not react 
with multiple partners).49 87 99 128 152 
Several groups have independently demonstrated that protein splicing 
precursors can be cut into two pieces that individually have no activity, but 
15 
w h e n c o m b i n e d they will non-covalently associate to give a functional intein 
(Figure 1.6).87 99 128 152 However, in vitro trans-splicing often requires 
denaturation and renaturation of the isolated precursor fragments.99 128 The 
denaturants may be required for multiple reasons: many intein fragments are 
insoluble when expressed separately,99 128 possibly due to improper folding or 
exposure of hydrophobic residues in the absence of the complete intein, 
alternatively, aggregation or insolubility could be due to the extein portion of 
the precursor fragment.128 
Protein trans-splicing is a bimolecular reaction. However, once the 
intein fragments reassemble, the reaction is, in effect, a uni-molecular 
reaction. Since non-allelic inteins have little sequence identity, different split 
inteins only re-associate with their homologous partners and not with 
HX 
MX 
, W b E r " k " 
-NH 
O A " C-terminal 
Extein 
N-terminal 
Extein " V 
Inte in 
Figure 1.6. Schematic representation of protein trans-splicing. T h e N-
terminal extein, C-terminal extein and the intein are shown in green, 
red and blue respectively. T h e intein is fragmented and inactive, but 
upon association activity is regained. 
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heterologous partners.109 Most recently, the protein trans-splicing area has 
received a considerable boost through the discovery of the naturally occurring 
split Synechocystis sp. (Ssp) DnaE intein.151 The dnaE gene encodes the 
catalytic subunit of the replicative DNA polymerase and is an essential gene. 
The two dnaE gene fragments are over 700 kilo bases (kb) apart on opposite 
strands of the Ssp. PCC6803 chromosome. Significantly, this split intein 
does not require denaturants for reconstitution to initiate splicing. This 
feature makes the Ssp. DnaE intein especially well suited for protein 
engineering applications. 
Applications of Protein Splicing. 
Understanding the protein splicing mechanism has led to the design 
of a number of mutant inteins which have significant utility in protein 
science and in particular, peptide ligation.62 Proteins expressed in-frame and 
amino-terminal to a mutated intein (Ans^Ala) that can only participate in 
the first step of splicing (i.e. the N-»S acyl shift, Figure 1.5 ®), can be 
cleaved by thiols via an intermolecular trans-thio-esterification reaction.27 It is 
also possible to mutate an intein such that after cleavage at the carboxy-
terminal splice junction one obtains the protein of interest with an amino-
terminal Cys.97 Importantly, the use of these engineered inteins permits the 
production of large recombinant building blocks for use with native chemical 
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ligation, and allows for mixing of recombinant and synthetic building blocks 
in chemical protein synthesis. 
Native chemical ligation is a technique that allows the chemo-selective 
addition of two unprotected peptides at physiological pH, with the resulting 
polypeptide containing a native backbone at the point of ligation.36 In this 
technique a peptide containing a C-terminal a-thioester group reacts with a 
second peptide containing an amino-terminal cysteine. Thiol exchange yields 
an intermediate linked through an a-thioester, which spontaneously rearranges 
to a peptide bond. Native chemical ligation can be performed in the 
presence of all the functionalities commonly found in proteins, including free 
cysteine sulfhydryls. Cysteine residues that are not N-terminal cannot 
spontaneously rearrange to give an amide bond, and due to the reversible 
nature of the initial trans-thio-esterification step, these side-products are simply 
converted back to starting materials in the presence of exogenous thiols. 
This advantage has made native chemical ligation the most successful and 
commonly used chemical ligation approach.35 Native chemical ligation 
(Figure 1.7) is the last step of protein splicing (Figure 1.5 ®) and their 
combination allowed the development of the protein semi-synthesis technique 
expressed protein ligation (EPL). 
EPL permits the ligation of two polypeptides, at least one of which is 
recombinant. This methodology is very flexible, allowing ligation of 
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Peptide 1 OJ. S. 
I P * H-lAl," I — Pepe.de iffi _ _ Pepcide ! " V 
Figure 1.7. Mechanism of native chemical ligation. The mechanism is 
explained in the text. 
polypeptides to take place under a variety of conditions, e.g. in the presence 
of denaturants, organic solvents, and detergents.7 In addition, the amino-
terminal OC-thioester fragment can contain essentially any residue next to the 
a-thioester.67 EPL has been used for the incorporation of probes into 
proteins in vitro (e.g. unnatural amino acids, fluorophores, post-translational 
modifications),7 the isotopic segmental labeling of multi-domain proteins,155 
and the backbone cyclization of peptides and proteins.20'22 
Protein trans-splicing has been used in a similar manner to EPL. The 
process has found a variety of applications in vitro, including protein semi-
synthesis,87 segmental isotopic labeling,157 control of protein function102 and 
cyclization or polymerization of proteins.48 In addition, split-inteins have 
been used to cyclize proteins in vivo48 126 and to study protein-protein 
interactions in prokaryotic and eukaryotic cells.111 112 The latter approach 
was first described in 2000 and allows protein-protein interactions to be 
identified in a manner reminiscent of the yeast two-hybrid system. T w o 
proteins known to interact (calmodulin and its target peptide Ml3) were 
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expressed with one half of the See V M A intein and one half of GFP. 
Interaction of calmodulin and M13 resulted in the generation of GFP via 
protein trans-splicing and hence the interaction could be detected by 
fluorescence techniques.111 This technique has been applied to other 
systems110 and adds to the growing number of reporter protein 
complementation approaches designed to rapidly identify novel protein-ligand 
interactions.133 Furthermore, it is attractive because it should be amenable 
to any cell type. 
Protein splicing has many features that make it amenable for the semi-
synthesis of proteins inside cells, namely; inteins are promiscuous with 
respect to their flanking sequences,72 and have demonstrated activity in 
cells.111 In addition, EPL is a powerful technique for in vitro manipulation 
of proteins,72 and one could expect an analogous technique in vivo, where a 
chemical probe is ligated to a protein inside cells, should also prove useful. 
Protein Transduction Domains. 
Passive diffusion of chemical probes into the cell is limited by the 
physical properties of the compound, such as charge and lipid solubility. 
There also exists a molecular weight cut-off that limits the size of the largest 
lipid-soluble substances able to cross the membrane to -500 Da.86 Though a 
variety of methods exist to overcome this limitation (e.g. electrophoresis, 
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microinjection, vesicle delivery), they have been difficult to work with and 
can damage cells. It was recently discovered that several small regions of 
proteins called protein transduction domains (PTD) possess the ability to 
transverse biological membranes efficiently. 
Two groups independently reported protein transduction, demonstrating 
that the Tat protein from the HIV-1 virus was able to enter cells when 
added to the surrounding media.56 64 Subsequently, several other proteins 
with transducing capabilities were identified, including the Drosophila 
homeotic transcription factor ANTP (encoded by the antennapedia gene)75and 
the herpes simplex virus type 1 (HSV-1) VP22 transcription factor.44 These 
are currently are the most popular. 
Table 1.1. Amino acid sequence of the first three characterized PTDs. 
PTD Amino acid sequence 
HIV-1 Tat "YGRKKRRQRRR" 
ANTP «RQIKIWFQNRRMKWKK58 
HSV VP22 »'DAATATRGRSAASRPTERPRAPARSASRPRRPE» 
The domains responsible for transduction in Tat, VP22 and ANTP 
have been identified. The minimal Tat transduction domain consists of 
residues 47-57,5052141 whereas in VP22 and ANTP, residues 267-30044 and 
21 
residues 43-58,39 respectively, are required for transduction (Table 1.1). 
Interestingly, all three of these proteins are involved in transcriptional 
regulation and it is the PTDs that make contact with nucleic acids. The 
commonality between each PTD is the presence of basic amino acids 
(arginine and lysine), which might be important for lipid interactions, 
penetration of the membrane, or both. Protein-structure-predicting algorithms 
strongly suggest that the Tat PTD can adopt an alpha helix conformation,91 
and the ANTP PTD is known to be helical when present in the core 
homeodomain. However, circular dichroism and NMR spectroscopy have 
indicated that the Tat basic domain is unstructured,1992 and the insertion of 
prolines into ANTP does not appear to inhibit transduction,37 suggesting that 
the helical conformation is not required for the PTDs activity. 
Although the mechanism of PTD-mediated transduction is unknown, it 
is clear that it does not occur through a classical receptor-, transporter- or 
endosome-mediated fashion.95 Indeed, both full-length PTD fusion proteins 
and PTD peptides rapidly and efficiently transduce into cells at 4°C, 
suggesting that a form of absorptive endocytosis is not responsible.37 141 
Additionally, treatment of cells with drugs that impair cellular transport 
processes does not inhibit transduction.44 The mechanism of protein 
transduction remains a difficult question to address experimentally, but 
progress has recently been made. In general, transduction efficiency appears 
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to correspond to the number and location of arginine residues in the P T D 
sequence. "When a series of arginine-rich peptides (derived from 14 RNA-
and DNA-binding proteins) were screened, they were all able to trans-locate 
through the cell membrane.57 Substitution of basic residues in Tat (49-57) 
produces a significant (70-90%) decrease in cellular uptake.148 Furthermore, 
the guanidine head-group of the arginine side-chain seems to be a critical 
structural feature for transduction. Homo-polymers of citrulline, an arginine 
isostere in which the nitrogen of the guanidine group is replaced with 
oxygen, show no transduction activity.148 Moreover, increasing the distance 
between the guanine group and the peptide backbone had a positive effect 
on cellular uptake.100 148 These observations suggest that the guanidine 
group is involved in the interaction of the PTD with the cell membrane. 
The guanidine group could be forming stable bi-dendate hydrogen bonds 
with anions such as phosphate or sulfate100 or the delocalized positive charge 
could be making membrane interactions more amicable. Thus, the 
internalization of arginine-rich PTDs seems to occur through a specific 
interaction between the arginine head-group and charged members of the cell 
membrane. These experiments are in accordance with the recent finding 
that cell-surface heparin sulfate (HS) proteoglycans are required for protein 
translocation (cells genetically impaired in the biosynthesis of fully sulfonated 
HS proteoglycans were selectively impaired for transduction).138 The 
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ubiquitous presence of H S could explain why Tat peptides and conjugated 
proteins are able to enter a wide variety of cells. However, it is still 
unknown how PTD-linked macromolecules are internalized following the 
interaction with the cell surface, and furthermore the HS PTD interaction 
fails to explain the ability of these peptides to shuttle out of cells (no HS 
are present in the cytosolic side of the membrane). 
A significant barrier to the uptake of hydrophilic proteins is imposed 
by the hydrophobic interior of the lipid membrane, and the uptake 
mechanism of PTDs must overcome this obstacle. The formation of 
membrane channels is unlikely to account for the internalization of large 
PTD-conjugated macro-molecules. In addition, Tat-mediated transduction does 





Figure 1.8. Inverted micelle formation model for the translocation of 
PTD across membranes. The peptides interact with the charged 
phospholipids on the outer side of the membrane. Destabilization of 
the bilayer results in the formation of an inverted micelle that travels 
across the membrane and eventually opens on its cytoplasmic side. 
In such a model the peptides never leave an aqueous environment. 
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not appear to involve any disruption of the plasma membrane, as uptake of 
unrelated non-conjugated peptides present in the incubation media could not 
be observed.141 The latter observation demonstrates a key asset of PTD-
mediated transduction: the ability to deliver a cargo, avoiding the movement 
of non-linked molecules into or out of the cell. NMR data has also 
demonstrated that the backbones of PTD peptides are flexible, presumably 
allowing them to adapt to the concave surfaces of micelles.16. Though a few 
models for translocation have been suggested, one of the most commonly 
cited is the inverted micelles translocation model38 (Figure 1.8). 
PTDs that are chemically cross-linked to heterologous proteins, such as 
antibodies and enzymes, have been shown to transduce into cells.3 53 In 
addition, the molecules that PTDs can deliver are not limited to proteins2 
(Figure 1.9). In 1991 Frankel stated: 
"Beyond the possible relevance for HIV infection, the efficiency of uptake 
suggests that Tat might prove a useful vehicle for delivering proteins or 
peptides into cells" Frankel.95 
In the P T D based delivery system, intracellular concentrations of the 
transduced protein are almost identical between cells and can be readily 
controlled simply by changing the amount of protein added to the culture 
media. Also, PTD fusion proteins are rapidly internalized allowing for 
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temporal control.143 For example, the fusion protein can be added to cells 
in a manner that is synchronized with a particular phase of the cell cycle 
with activity occurring within minutes of protein addition. The same 
experiment performed with plasmid DNA transfections would be impossible 
because of the large delay between DNA uptake and protein expression. To 
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Figure 1.9. Utility of protein transduction technology. A wide variety 
of cargo has been covalently linked to arginine-dependent protein 
transduction domains (PTDs). 
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Protein transduction has also been shown to be advantageous over 
viral transgene delivery in vivo (e.g. whole animals). Injection of a Tat-
conjugated protein results in transduction of 1 0 0 % of the cells in a 
concentration-dependent manner, whereas viral delivery achieves only 30-50% 
efficiency.13 14. Although PTDs have been used extensively, they are not 
silver bullets. For example, proteins transduced with T A T are denatured,23 
and the translocation activity of A N T P is greatly reduced with increased 
cargo size.119 These latter characteristic may not be ideal for all applications, 
but PTDs are well suited to deliver small, un-structured synthetic molecules 
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into cells. In conjunction with protein splicing, PTDs presented a viable 
route to investigate semi-synthetic protein synthesis in vivo. 
28 
Thesis Objectives 
The objective of this thesis was to explore the union of PTD and 
protein splicing in order to achieve protein semi-synthesis in living cells. 
First, PTD peptides were evaluated as a means to introduce in vitro 
manipulated peptides and proteins into cultured eukaryotic cells. Then, 
protein trans-splicing was explored to address the possibility of in vivo protein 
semi-synthesis in cells. Lastly, there was a slight divergence from the main 
focus of the thesis for the exploration of the utility of semi-synthetic proteins 
as a tool to answer biological questions in the context of whole animals. 
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Chapter 2: Results a n d Discussion. 
Incorporation of chemically manipulated peptides and proteins into 
cultured mammalian cells using PTDs. 
A key feature for the development of protein semi-synthesis inside cells 
is the need to shuttle the synthetic component into the cytosol. PTD 
peptides have the ability to translocate through cellular membranes and 
transport cargo molecules into the cytosol of cells (see chapter l).143 ANTP 
was selected for this thesis because its small size, 16 amino acids, makes it 
amenable for SPPS. 
Three methods are typically used for coupling the cargo molecule to 
the PTD. The cargo may be attached via a disulfide bond136, chemically 
synthesized in tandem68 or a fusion protein comprising the PTD and cargo 
can be expressed in bacteria and purified15 (Figure 2.1). 
To explore the translocation activity of ANTP in preliminary 
experiments, the PTD was synthesized in tandem within a 70 amino acids 
model polypeptide, derived from DnaE, by Boc SPPS. The fluorophore 
tetramethylrhodamine (Rh) was attached to the £-NH2 group of Lys6' using an 
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C iPTDl Cargo""" 
Affinity tag 
Figure 2.1. Methods for coupling P T D peptides to a cargo. (A) The 
cargo and PTD can be synthesized separately and attached through a 
disulfide bond. (B) The cargo and PTD can be chemically 
synthesized in tandem. (C) A fusion protein comprising the PTD 
and cargo can be expressed in bacteria and purified. 
orthogonal (Fmoc/Boc) protection strategy. (Peptide 1, ANTP is highlighted 
in blue and Rh in red). 
Peptide 1: 
H - M V K V I G R R S L G V Q R I F D I G L P Q D H N F L L A N G A I A A N C F G C G R Q I K I 
W F Q N R R M K W K K G G D Y K D D D D K G K ( R h ) G - N H 2 
The purified peptide was added into the media of HeLa cells growing 
in a microscopy chamber to a final concentration of 1 nM. After 30 
minutes incubation, the cells were washed with Hanks' balanced salt solution 
(HBSS) and imaged live with a fluorescence microscope. A N T P was able to 
translocate the 70mer (Peptide 1) into cells (Figure 2.2 A) and over a period 
of an hour it accumulated in the nucleus (Figure 2.2 B). This nuclear 
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Figure 2.2. Localization of peptide 1. (A) Microscopy imaging of 
HeLa cells after 30 minutes incubation with 1 n M peptide 1 
confirmed translocation. (B) An hour after removing peptide 1 from 
the media, the internalized peptide accumulates in the nucleus. 
accumulation is well documented for PTDs, including ANTP,119 most of 
which have nuclear localization sequences (NLS). 
The nuclear localization of peptide 1, due to the tandem inclusion of 
A T N P , would ultimately lead to the separate compartmentalization of the 
components of semi-synthesis (nucleus vs. cytosol) and could prevent the 
process. Previous studies have shown that PTDs can internalize disulfide 
bound cargo and, once inside the reductive environment of the cytoplasm, 
the cargo is released from the PTD.134 135 To verify this, a protocol was 
developed that allowed a cargo peptide, derived from DnaE (Peptide 2), to 
be coupled to A N T P through a disulfide bond (Figure 2.3 A). 
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Peptide 2 (later referred to as I^FLAG): 
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAANCFN 
D Y K D D D D K G - N F L 
A N T P and peptide 2 were separately synthesized by Boc SPPS and purified. 
As shown in figure 2.3 A, a protected cysteine residue was added at the N-























fc. — 1 = 5 ' 
\r-~_ 
fi^-
22 " t/min 
Figure 2.3. Coupling of peptide 2 to Cys(NPyS)ANTP. (A) General 
scheme for the synthesis of ANTP-S-S-Peptide 2 via a nucleophilic 
disulfide exchange. The amino acid sequence of peptide 2 and 
ANTP are depicted in purple and blue respectively. Highlighted in 
orange or in bold are he NPyS group on ANTP and the single Cys 
in peptide 2, respectively. (B) RP-HPLC analysis of the conjugation 
reaction between Cys(NPyS)ANTP and peptide 2. Linear gradient: 0-
73% B (90% acetonitrile and 0.1% TFA in water) over 30 minutes. 
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terminus of ANTP. The sulfhydryl group was protected with a 3-nitro-2-
pyridinesulfenyl group (NPyS, highlighted in orange in Figure 2.3 A), which acts as 
a leaving group upon nucleophilic disulfide exchange with the unique cysteine 
within peptide 2 (highlighted in bold). After purification, the peptides were 
dissolved together in degassed 50 mM Tris/HCl buffer pH 7.5 to a concentration 
of 1 mM in each. The nucleophilic disulfide exchange reaction was allowed to 
proceed for 5 minutes at room temperature (becoming visibly yellow as the NPyS 
group was being displaced), and then quenched with acid. This reaction allowed 
highly efficient (>95%) conjugation of the cargo to ANTP (Figure 2.3 B), and un-
reacted starting material could be recovered for re-use. 
Two disulfide conjugates were used to study if the disulfide conjugation 
system allowed delivery of the cargo into the cytoplasm; one bearing Rh tethered to 
the ANTP component (Rh-ANTP), and the other with Rh linked to peptide 2 
(Peptide 2-Rh). These peptides were independently added onto HeLa cells (to a 
final concentration of 2 nM), which were then incubated for 30 minutes before 
being washed twice with PBS and fixed with 3.7% formaldehyde, followed by BSA 
blocking and nucleic acid staining with Hoechst. The fixed cells were then 
analyzed by fluorescent microscopy. As shown in Figure 2.4 A, the Rh-ANTP 
peptide was localized throughout the cells, including the nucleus, whereas peptide 2-
Rh was predominantly localized in the cytoplasm (Figure 2.4 C). This result 
confirmed that the disulfide reduction was taking place inside the cells, dissociating 
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the cargo from the PTD and leaving it behind in the cytosol, where it can later 





Figure 2.4. Cellular distribution of ANTP-S-S-Peptide 2 Rh-labeled 
peptides. HeLa cells were incubated with either Rh-ANTP-S-S-Peptide 
2 (A & B) or ANTP-S-S-Peptide 2-Rh (C & D) at 2 nM for 30 
minutes before being washed and fixed. Cells were then analyzed by 
fluorescence microscopy: Rh (A & C) and Hoechst (B & D) signals 
are shown. 
Translocation and delivery of short synthetic peptides into cells was achieved 
using ANTP as the PTD. ANTP was able to transverse the membrane of 
mammalian cells imbedded in a 70mer. Furthermore, ANTP could translocate a 
disulfide linked 48mer, and dissociate from it inside the reductive environment of 
the cytosol. The cargo peptide was left in the cytoplasm of living cells to undergo 
further reaction (e.g. protein semi-synthesis). 
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Protein semi-synthesis in vivo using protein trans-splicing. 
Protein trans-splicing has many of the attributes necessary for the semi-
synthesis of proteins inside cells: inteins are promiscuous with respect to 
their flanking sequences,72 split inteins are inactive when expressed 
individually,87 " 128 152 they associate exclusively with their corresponding 
partner,109 and, specifically for the Ssp DnaE system, the components have 
high affinity for each other.96 
The methodology summarized in Figure 2.5 was envisioned to produce 
semi-synthetic proteins in living cells using protein trans-splicing. 
The protein of interest is expressed in cultured cells with the first half 
of the naturally occurring Ssp DnaE split intein (L) fused to its C-terminus 
(Figure 2.5 (D). Then, a semi-synthetic polypeptide comprised of the second 
half of the intein (L) covalently linked to a synthetic probe and a PTD 
peptide, is added to the cell media (Figure 2.5 ®). The PTD peptide 
would deliver the Ic-probe into the cells, whereupon it can associate with its 
complementary half, L, to trigger protein splicing (Figure 2.5 (D). This 
would result in the removal of the intein and ligation of the probe to the 
selected protein through a normal peptide bond (Figure 2.5 ®). To explore 




Figure 2.5. Principle of semi-synthetic protein trans-splicing in living 
cells. L is the first half of the naturally occurring Ssp DnaE intein, 
L is its second half and P T D is protein transduction domain. 
interest was G F P and the probe was a short synthetic peptide, based on the 
F L A G epitope. 
Initially, a bacterial expression plasmid was constructed encoding 6xHis-
GFP-L, in order to produce large enough quantities to perform preliminary 
in vitro trans-splicing studies. A standard His-tag purification protocol was 
used to obtain the protein in relatively pure form (Figure 2.6). 
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To confirm that protein trans-splicing could take place between the 
components of the chosen model system, the bacterially expressed 6xHisGFP-
L was reacted with Ic-FLAG at a final concentration of 100 |lM. (Ic-FLAG = 
peptide 2. L and FLAG are highlighted in purple and red, respectively) 
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Figure 2.6. Expression and purification of 6xHis-GFP-L from E. 
coli. The level of expression induced in bacteria was very high. 
The bacterial pellet (A) was bright green when illuminated with 
UV light (B). (C) Analysis of the purification procedure by 
SDS-PAGE gel showed that most (>90%) of the protein was 
insoluble (6xHis-GFP-L is denoted by *), but enough was 
recovered to perform in vitro experiments. 
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The reaction mixture was incubated at room temperature for 5 hours 
and was then analyzed by SDS-PAGE (12%) followed by an anti-FLAG 
western blot (Figure 2.7). As shown in the figure, trans-splicing takes place 
between 6xHis-GFP-L and L-FLAG, yielding 6xHisGFP-FLAG as the only 
splice product (Figure 2.7 lane 2). 
Having thus confirmed that semi-synthetic protein trans-splicing was 
taking place in vitro, and that Ic-FLAG could enter cells (see previous section), 
experiments to address semi-synthetic protein trans-splicing in vivo were 
undertaken. A mammalian expression plasmid was constructed encoding 
GFP-L driven by the human cytomegalovirus (CMV) constitutively active 
promoter (pGFP-L). To confirm expression in mammalian cells, CHO cells 
were transiently transfected with pGFP-L using Fugene. After 24 hours of 
1 2 
il 






Figure 2.7. Anti-FLAG western of in vitro semi-synthetic protein trans-
splicing. 6xHisGFP-L with no peptide added (lane 1) and 6xHisGFP-
L with 100 (iM of L-FLAG present (lane 2). The product, 
6xHisGFP-FLAG, is denoted by *, and its expected mass is 29 kDa. 
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expression the cells were washed twice with PBS and harvested. The cell 
pellet was resuspended in SDS sample buffer and loaded onto an SDS-PAGE 
gel (12%) for blotting against GFP (Figure 2.8), which verified the expression 
of GFP-L. 
HeLa cells were also transiently ttansfected with pGFP-L to visualize the 
localization of the fusion protein. After 24 hours of expression the cells were 
washed twice with PBS and fixed with 3.7% formaldehyde, followed by BSA 
blocking and nucleic acid staining with Hoechst. As seen in figure 2.9 GFP-L was 
distributed throughout the cell. 
With the individual pieces in place, semi-synthetic trans-splicing inside cells 






Figure 2.8. Mammalian expression of GFP-L. Anti-GFP western blot 
of un-transfected CHO cells (lane 1) and CHO cells transfected with 
pGFP-L (lane 2). GFP-L is denoted by •, and its expected mass is 
42 kDa. Background bands are denoted by < and proteolysis 
products by ©. 
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24 hours of transient expression, the cells were washed twice with 10 m L of PBS 
and fresh media (2.5 mL) containing 0.5% DMSO or 0.5% DMSO with the 
ANTP-S-S-Ic-FLAG peptide added to a final concentration of 100 |iM. The cells 
were then incubated for three hours before being harvested. The cell pellet was 
resuspended in 1 mL of lysis buffer: PBS containing 1% (w/v) docecylmaltoside 
(DM), 10 mM iodoacetamide, 2 mM N-ethyl-maleamide and protease inhibitors. 
Lysis under alkylating conditions blocks all cysteine sulfhydryl groups, therefore 
preventing splicing in vitro. The soluble fraction was immuno-precipitated with anti-
GFP or anti-FLAG beads and the captured proteins were loaded onto an SDS-
PAGE gel and blotted against GFP or FLAG. This procedure allowed us to detect 
the presence of proteins containing either GFP or FLAG alone (i.e. the reactants 
or potential side-products) or both GFP and FLAG (i.e. the desired product). The 
results of this experiment are shown in Figure 2.10. 
Figure 2.9. Cellular localization of GFP-L in HeLa cells. The image 
shows that GFP-L is distributed throughout the cell. 
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A band with the expected molecular weight for the semi-synthetic 
product (-29 kDa) appeared when transfected cells were treated with the 
ANTP-S-S-L-FLAG peptide (lanes 4, 8, 12 and 16). Importantly, this new 
band cross-reacted with both the anti-GFP and anti-FLAG antibodies 
confirming it was the desired product, GFP-FLAG. In contrast, this new 
band was not present in non-transfected and untreated cells (lanes 1, 5, 9 
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Figure 2.10. Semi-synthetic trans-splicing between G F P - L and L - F L A G 
in CHO cells [schematically shown in top panel]. Cells treated as 
indicated below were lysed and the soluble fraction immuno-
precipitated and blotted as indicated in the panels. Non-transfected 
and untreated cells (lanes 1, 5, 9 and 13), non-transfected cells 
treated with 100 [iU ANTP-S-S-L-FLAG (lanes 2, 6, 10 and 14), 
transfected cells expressing GFP-L with no peptide added (lanes 3, 7, 
11 and 15) and transfected cells expressing GFP-L treated with 100 
UM ANTP-S-S-Ic-FLAG (lanes 4, 8, 12 and 16). The ligation product 
GFP-FLAG is denoted by *, GFP-L is denoted by •, background 
bands are denoted bv < and proteolysis products are denoted bv ©. 
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(lanes 2, 6, 10 and 14) and transfected cells with no peptide added (lanes 3, 
7, 11 and 15). 
Interestingly, GFP-L co-immuno-precipitated with L-FLAG (lane 8) 
indicating a non-covalent complex between the two components. This 
suggests that protein splicing, and not split-intein association, is the rate-
determining step in the process, which is in accordance with previous studies 
on Ssp DnaE-mediated protein trans-splicing.96 Furthermore, co-immuno-
precipitation of GFP-L but not of the proteolysis products, suggested that the 
3 4 5 6 
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Figure 2.11. Semi-synthetic protein trans-splicing takes place in cells. 
(A 6k B) Transfected cells expressing GFP-L with no peptide added 
at the time of lysis (lane 1 & 3) and transfected cells expressing 
GFP-L treated with 50 uL of 100 JIM Ic-FLAG at the time of lysis 
(lane 2 & 4). (C) Transfected cells expressing GFP-L treated with 
100 fxM ANTP-S-S-L-FLAG (lane 5) and transfected cells expressing 
GFP-L mixed at the time of lysis with non-transfected cells treated 
with 100 mM ANTP-S-S-Ic-FLAG (lane 6). The ligation product GFP-
FLAG is denoted by *, GFP-L is denoted by •, proteolysis products 
are denoted by © and background bands are denoted by <. 
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degradation of the over-expressed protein was taking place C-terminally (at L) 
(lane 3 (St 4, indicated by 0); proteolytic fragments were not associating or 
reacting with Ic-FLAG. 
The anti-FLAG IP analysis also demonstrated that the trans-splicing 
reaction is specific as only one protein was tagged with FLAG (lane 16). 
The efficiency of the semi-synthetic protein trans-splicing reaction could not 
be easily determined, because GFP-L was being continually expressed (and so 
therefore not depleted) and because the ANTP-S-S-Ic-FLAG peptide was added 






Figure 2.12. FLAG labeling of GFP is due to protein splicing. 
Transfected cells expressing GFP-L treated with 100 uM ANTP-S-S-L-
FLAG (lane 1), transfected cells expressing GFP-L treated with 100 
UM ANTP-S-S-L(S-R)-FLAG (lane 2) and transfected cells expressing 
GFP-L(Ala-) treated with 100 uM ANTP-S-S-Ic-FLAG (lane 3). The 
ligation product GFP-FLAG is denoted by *, GFP-L is denoted by • 
and background bands are denoted by <. 
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unequivocal proof that Ic-FLAG was released from A N T P since this process 
(i.e. disulfide reduction) unmasks the reactive cysteine within L required for 
splicing. 
Further control experiments were performed to completely rule out the 
possibility that splicing was taking place in vitro (i.e. after lysis). The issue 
was addressed in two ways. The first experiment consistent in adding 50 flL 
of 100 |LtM of Ic-FLAG onto the cells at the time of lysis (Figure 2.11 A & 
B) .The second experiment consistent in mixing transfected cells expressing 
GFP-L, but not treated with the peptide, with non-transfected cells treated 
with the peptide at the time of lysis (Figure 2.11 C). The two components 
of the trans-splicing system were present throughout the in vitro manipulations 
in both cases, such that, if trans-splicing was taking place after lysis, the 
activity should be detected. As shown in Figure 2.11, no splicing or split-
intein association was detected (compare lanes 1 & 2, 3 <Sc 4 and 5 <St 6). 
To confirm that product formation was due to protein splicing, an 
experiment was performed using inactive forms of L or L. The reactive 
cysteine in L was mutated to an alanine (GFP-L(Ala250) and reactive cysteine 
in L was alkylated and an extra cysteine added onto the N-terminus of the 
peptide for disulfide linkage to ANTP (L(S-R)-FLAG). Although the inactive 
L and L analogs were able to associate with their complementary 
component, in neither case was trans-splicing observed (Figure 2.12, lanes 2 
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Figure 2.13. Generality of protein semi-synthesis in vivo. (A) Anti-GST 
western blot of 12% SDS-PAGE gel of un-transfected and untreated 
cells (lane 1), cells transfected with pGST-L left untreated (lane 2) 
and cells transfected with pGST-L treated with peptide (lane 3). The 
product GST-FLAG is denoted by *, and its expected mass is -28 
kDa. The precursor GST-L is denoted by •. (B) Anti-FLAG western 
blot of a 15% SDS-PAGE gel of un-transfected and untreated cells 
(lane 4), cells transfected with pDHFR-L left untreated (lane 5) and 
cells transfected with pDHFR-L treated with peptide (lane 6). The 
product DHFR-FLAG is denoted by *, and its expected mass is 
-24.5 kDa. (C) Anti-GFP western blot of a 15% SDS-PAGE gel of 
un-transfected and untreated cells (lane 7), cells transfected with 
pYFP-In-CFP left untreated (lane 8) and cells transfected with pYFP-L-
CFP treated with peptide (lane 9). The product YFP-FLAG is 
denoted by ~k and its expected mass is -29 kDa. Background bands 
are denoted by <. 
&. 3). Thus product formation occurs via protein trans-splicing in the living 
cells. 
To explore the generality of protein semi-synthesis in vivo, Ic-FLAG was 
reacted with three other model cytosolic proteins: GST-L, DHFR-L and YFP-
In-CFP and in each case the desired semi-synthetic product was obtained 
46 
(Figure 2.13). Interestingly, the later construct (YFP-L-CFP) s h o w e d improved 
cytosolic expression as compared to GFP-L (Figure 2.14), suggesting that 
inserting L between two domains may help soluble expression of the fusion 
protein. In addition, trans-splicing resulted in cleavage of YFP from L-CFP, 
indicating that the methodology may also serve as a tool to trigger the un-
coupling of fusion proteins in vivo. 
In principle, the protein semi-synthesis approach based on protein 
trans-splicing should also be applicable to integral membrane proteins. This 
possibility was investigated by preparing a semi-synthetic version of the G-
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Figure 2.14. Comparison of whole cell vs. detergent soluble or insoluble 
expression of GFP-L and YFP-L-CFP. CHO cells were transiently 
transfected with either pGFP-L (A) or pYFP-L-CFP (B) and after 24 
hours of expression the cells were lysed in PBS + 1% DM. Whole 
cell (lanes 1 & 4), soluble (lanes 2 &. 5) or detergent insoluble 
fraction (lanes 3 & 6) samples were loaded for analysis onto a 12% 
PAGE-SDS gel and blotted against GFP. In the case of GFP-L 
>90% of the protein is insoluble (compare lanes 2 & 3) vs. -50% in 
the case of YFP-L-CFP (compare lanes 4 & 5). GFP-L is denoted by 
•, and its expected mass is -42 kDa. YFP-In-CFP is denoted by A, 
and its expected mass is -74 kDa. 
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protein-coupled receptor (GPCR), Opsin. As shown in Figure 2.15, Opsin-
GFP-FLAG was generated by treating transfected cells expressing Opsin-GFP-L 
with ANTP-S-S-L-FLAG (compare lane 3 with control lanes 1 ek 2). 
Importantly, the smearing of the band corresponding to the ligation product, 






Figure 2.15. Semi-synthetic trans-splicing between Opsin-GFP-L and L-
FLAG in CHO cells [schematically shown in top panel]. Cells treated 
as indicated below were lysed and the soluble fraction immuno-
precipitated and blotted as indicated in the panel. Non-transfected 
and untreated cells (lane 1), transfected cells expressing Opsin-GFP-L 
with no peptide added (lane 2) and transfected cells expressing 
Opsin-GFP-L treated with 100 uM ANTP-S-S-Ic-FLAG (lane 3). The 
ligation product (Opsin-GFP-FLAG) is denoted by *, background 
bands are denoted by <, and the smearing in the band is due to the 
glycosylation of Opsin. The expected molecular weight of Opsin-GFP-
FLAG is -70 kDa. 
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occur during membrane integration.77 
Preliminary experiments were performed to determine the minimum 
concentration of ANTP-S-S-L-FLAG needed to observe semi-synthetic trans-
splicing within 3 hours of incubation (Figure 2.16). CHO cells expressing 
GFP-L for 24 hours were treated for 3 hours with varying concentrations of 
ANTP-S-S-L-FLAG. Following harvest and immuno-precipitation against 
FLAG, samples were analyzed by western blotting against GFP. As seen in 
figure 2.16, a minimum of 50 LiM was required to observe activity or 
association of the fragments at this time point. This observation is rather 
12 3 4 5 6 7 






Figure 2.16. Minimum concentration of L-FLAG necessary to observe 
semi-synthetic protein trans-splicing in cells. Un-transfected and non-
treated cells (lane 1), transfected cells expressing GFP-L with no 
peptide added (lane 2) and transfected cells expressing GFP-L treated 
with 100 uM (lane 3), 50 oM (lane 4), 10 JlM (lane 5), 5 |lM (lane 
6) or 1 (iM (lane 7). Product formation or intein association is only 
seen at 100 or 50 [iM (lanes 3 6k 4). The ligation product GFP-
FLAG is denoted by *, GFP-L is denoted by • and background 
bands are denoted by <. 
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surprising, as literature reports have suggested that the dissociation constant 
(Kd) between L and L is in the nano-molar range.96 The possibility that 
only a small percentage of the L-FLAG is being translocated is unlikely, 
because transduction of both ANTP and Ic-FLAG was observed at 2 nM (see 
previous sub-section). Future experiments will be required before the origins 
of this observation are known. 
Although protein semi-synthesis based on trans-splicing allows 
ligation to both cytosolic and membrane bound proteins in vivo, the 
technique is not without drawbacks. Addition of L to the C-terminus of 
proteins affects their solubility, and in the case of membrane bound proteins, 
their localization. Solubility problems with split inteins have been previously 
reported and can possibly be due to improper folding or exposed 
hydrophobic regions.99128 As seen in figure 2.14 (compare lanes 2 <Sc 3) 
most of the GFP-L is expressed in an insoluble form. To partially overcome 
this issue, L was inserted between two GFP proteins to stabilize it and 
increase its solubility (Figure 2.14, compare lanes 2 <Sc 3 with 5 <Sc 6). This 
protocol also increased expression of the membrane bound transferrin 
receptor (TnfR) tagged with GFP-L (Figure 2.17, compare B & C), but did 
not overcome the undesired (e.g. endoplasmic reticulum (ER)) localization 
observed with the tandem expression of TnfR and L. As seen in figure 
2.17, TnfR-GFP localizes to the cell surface of mammalian cells as desired 
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Figure 2.17. Localization of TnfR-GFP, TnfR-GFP-L and TnfR-YFP-L-CFP 
in MCF-7 cells. Cells were transiently transfected and allowed to express 
the proteins for 24 hours, before being fixed. (A) TnfR-GFP is 
localized to the plasma membrane. (B) TnfR-GFP-L does not localize to 
the plasma membrane, and is scarcely visible. (C) TnfR-YFP-L-CFP does 
not localize to the plasma membrane, but it expresses better then TnfR-
GFP-L. GFP (A & B) or YFP (C) fluorescence signal is shown. 
(Figure 2.17 A ) , contrary to both TnfR-GFP-L and TnfR-YFP-lN-CFP, which 
appeared to be largely retained in the E R (Figure 2.17 B &. C). This type 
of undesired localization was also observed with Opsin-GFP-L (Figure 2.18 
compare A &. B). 
In a previous study, Ozawa et. al. attached L to membrane bound 
proteins, but did not visualize their localization.110 Improper folding or 
exposure of hydrophobic residues of L may also be responsible for the 
inadequate delivery of membrane proteins. Additionally, the size of L (123 
amino acids) could have an effect, analogous to that observed in some cases 
w ith G F P tagging. Further studies on L may reveal a way to make this 
intein fragment behave better. Mutagenesis, or minimization of L could 
improve its characteristics. Alternatively, inverting the system (e.g. L tagged 
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Figure 2.18. Localization of Opsin-GFP and Opsin-GFP-L in HeLa cells. 
Cells were transiently transfected and allowed to express the proteins for 
24 hours, before being fixed. (A) Opsin-GFP is localized to the plasma 
membrane. (B) Opsin-GFP-L does not localize to the plasma membrane. 
G F P fluorescence signal is shown. 
to the protein of interest and L used to deliver the probe) could all 
together by-pass these solubility and localization problems as L is small and 
seemingly well behaved (see below). 
While Ic-FLAG was synthesized by SPPS for this study, a semi-synthetic 
protocol for the addition of probes onto L was also developed for ease and 




Figure 2.19. General scheme for the addition of a probe onto L. Ic-GyrA-
C B D is expressed in bacteria and purified using the chitin binding 
domain (CBD) or other affinity tag. Once purified it can react with a 























Figure 2.20. Bacterial expression and purification of Ic-GyrA-CBD. The 
fusion protein was soluble, and was induced to very high levels (-50% 
of the total bacterial proteins). Ic-GyrA-CBD is denoted by •, and its 
expected mass is 32 kDa. 
A bacterial expression plasmid was constructed with L N-terminally 
fused to the mutated Gyrase A (GyrA) intein followed by a chitin binding 
domain (CBD) (pIc-GyrA-CBD). Expression was induced to high levels in E. 
coli, and the soluble fusion protein was purified over chitin beads (Figure 
2.20). 
The GyrA intein within the purified fusion protein was functional and 
permitted EPL between L and peptide 3 to take place in yields of > 9 0 % 
(Figure 2.21). The product (L-Peptide 3) bound non-specifically to chitin 
beads, but was effectively eluded with a solution containing 8 M urea. 
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Figure 2.21. L-GyrA-CBD is functional and undergoes EPL. Untreated 
protein (lane 1), protein cleaved with 100 m M M E S N A (lane 2), 
protein treated with 1 m M of peptide 3 is unmodified (lane 3) and 
protein treated with 100 m M M E S N A and 1 m M of peptide 3 
produces the expected product Ic-Peptide 3. Full length Ic-GyrA-CBD 
is denoted by •, cleave GyrA-CBD is denoted by ®, and the EPL 
product Ic-Peptide 3 is denoted bv *. 
Peptide 3: 
H- CGRGK(Rh)G-NH, 
Protein semi-synthesis in vivo based on protein trans-splicing was 
successful. In principle, any synthetic molecule - a polypeptide or, minimally, 
a cysteine derivative bearing any chemical moiety - can be ligated to a 
protein of interest inside living cells. Here, incorporation of the probe took 
place at the C-terminus of the protein, however, by interchanging the split 
intein components, it should be possible to introduce the probe at the N-
terminus of a protein as well. Such a possibility increases the modularity of 
the approach. Future experiments will be performed in the laboratory to 
explore N-terminal ligations. 
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Semi-synthetic growth factor derivatives for whole animal studies. 
TTiis work was done in collaboration with Rob Flavell and Amersham Health. 
Growth factors are extra-cellular polypeptide signal molecules that 
stimulate a cell to grow, proliferate, differentiate or survive.85 They circulate 
in the blood stream and have specific receptors on the surface of target 
cells. Most animal cells require a precise combination of several growth 
factors to multiply, highlighting the combinatorial nature of the associated 
signaling pathways, and the need to study these polypeptides imbedded 
within their in vivo system. Furthermore, growth factors are tightly associated 
with the uncontrolled cell division seen in tumors and cancer.85 These 
characteristics make growth factors an interesting and suitable proof-of-
principle system for the investigation of protein semi-synthesis as a tool for 
whole animal studies. Initially, the vascular endothelial growth factor (VEGF) 
was chosen as a model protein. 
VEGF is a critical regulator of angiogenesis, the formation of new 
blood vessels, and plays an important role in vascular development and 
wound healing.55 VEGF-mediated angiogenesis is also implicated in a variety 
of pathological conditions, most notably the vascularization of solid tumors. 
Thus, there is great interest in understanding the role of VEGF in normal 

















Figure 2.22. Splice variants of h u m a n V E G F . The human V E G F gene, 
through alternative splicing produces 5 iso-forms, which differ in the 
presence or absence of heparin binding domains. Black and red 
represent the pro-peptide sequence and the receptor-binding domain, 
respectively. Other colors represent heparan-sulfate proteoglycan (HSPG) 
binding domains encoded by different exons. VEGFuo is the proteolytic 
product of VEGF.65 or VEGFis.. 
exploited for the development of new therapies for disorders like cancer.54 
V E G F is a homo-dimeric, disulfide-linked glycoprotein that is secreted into 
the extra-cellular space. It has multiple splice variants (Figure 2.22), all of 
which contain a signal peptide sequence for secretion and heparin binding 
domains. In the case of VEGFies and VEGFi89, the heparin binding domains 
can be cleaved off by the protease plasmin, producing the freely circulating 
VEGFuo.55 
V E G F binds to specific receptors, including V E G F R - 1 and V E G F R - 2 
(Figure 2.23), with pico-molar affinities. These receptors are expressed 
predominantly in endothelial cells and can be up-regulated under hypoxic 
conditions or by the increase in ligand concentration that occurs during 
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angiogenesis. High concentrations of VEGFR-1 and VEGFR-2 serve as 
markers of active angiogenesis.55 For these reasons, VEGF has been used in 
several studies to deliver specific cytotoxic proteins to cells expressing VEGF 
receptors as a potential cancer therapy.5 8 9 
A circulating variant of VEGF, such as VEGFuo, coupled with an 
appropriate imaging tag, could be used as a probe to detect angiogenesis in 
whole animals. VEGFuo lacks heparin-binding activity, potentially increasing 
its bio-availability,80 but maintaining its high affinity for VEGFR-1 and 
VEGFR-2. As endothelial cells are among those exhibiting the lowest 
replication level in the body, (with only 0.01% cells engaged in cell division 
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Figure 2.23. Main V E G F receptors. The three signaling tyrosine-kinase 
receptors of the V E G F family (VEGFR-1, VEGFR-2 and VEGFR-3) are 
shown. V E G F is also known to bind the accessory iso-form specific 
receptors neuropilin-1 and neuropilin-2, and heparan-sulfate proteoglycans. 
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onto VEGFR-1 and VEGFR-2 should concur with sites of angiogenesis (e.g. 
tumors). 
Synthetic chelators of the radio-isotope ""To have been conjugated to a 
variety of peptides, and used to image pathological events such as blood 
clotting, inflammation, infection, and cancer.26 122 158 In particular, 
epidermal growth factor has been labeled with "mTc and used to image 
tumors in mice.121 Antibodies and other proteins have also been labeled 
with "°Tc through standard conjugation methods, including alkylation of 
reduced cysteines, biotin-avidin interactions, or the addition of specific "°Tc 
chelating peptide sequences.58 59 144 
"mTc has proven to be a versatile isotope because it is a pure y 
emitter with optimal emission energy of 140 keV, ideal for use with y 
cameras employed in nuclear medicine.4 Additionally, its half-life of 6 hours 
and ease of production using a MMo/""Tc generator make it well suited for 
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Figure 2.24. Diamine, dioxime chelates bind "°Tc in a pyramidal 
complex. Loading of w™Tc is achieved under reducing conditions at 
p H 9.0. The covalent interaction is stable under physiological 
conditions. 
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diagnostic use. A variety of high affinity synthetic chelators for "°Tc have 
been developed12 (see below) and loading with "-To is a relatively simple 
procedure (Figure 2.24). 
The methodology summarized in Figure 2.25 was envisioned to 
produce semi-synthetic VEGF with a small imaging tag that chelates "°Tc 
with high affinity. Following protein semi-synthesis, the ""Tc would be 
incorporated into the protein and allow imaging of the proteins' localization 
to vascularized tumors. 













Figure 2.25. General scheme to investigate the use of semi-synthetic proteins 
produced by EPL in whole animal studies. VEGF was chosen as a model 
protein to be tagged with a WnTc chelator. The semi-synthetic protein 
could allow imaging of tumors in animals. 
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modified GyrA intein. A synthetic cysteine derivative containing a high 
affinity chelator of 99mTc is then reacted with the purified protein, resulting 
in a semi-synthetic form of VEGF tagged with the chelator (Figure 2.25 CD). 
In the next step, the semi-synthetic protein is loaded with "°Tc and injected 
into mice bearing a human tumor (Figure 2.25 ® &. ©). Imaging of the 
mice with a y-camera would allow the localization of VEGF to be visualized 
(Figure 2.25 © <Sc ®). This project was conceived in collaboration with 
Amersham Health, one of the world's leading biomedical imaging companies. 
In addition, VEGF, a disulfide linked dimeric protein, would further test the 
scope of the EPL methodology. 
The crystal structure of VEGFmo5 in complex with the VEGF binding 
domain of VEGFR-1 has been solved.149 Analysis of the structural data 
shows that the C-terminus of VEGF8.io9 is not involved in receptor binding. 
Moreover, mutagenesis of this region has little effect on VEGFR binding.81 
Therefore, to minimize possible disruption of the interaction between VEGFuo 
and its receptors due to an unnatural moiety, the ""Tc chelator was ligated 
onto the C-terminus of VEGFuo. An affinity handle was later attached to 
the chelator because in preliminary studies, hydrolyzed material could not be 
resolved from the ligation product (see below) (Figure 2.26). 
VEGFuo was expressed in E.coli N-terminally fused to the cleavable 
intein GyrA and a CBD. The majority of the fusion protein was expressed 
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in inclusion bodies. These were washed with a solution containing 2 M 
urea to remove loosely associated proteins, before being solubilized with a 
solution containing 8 M urea. Previous work in the Muir laboratory has 
shown that GyrA can be refolded from inclusion bodies and it regains 
protein splicing activity.139 Such a characteristic makes GyrA a suitable intein 
for fusion with VEGFuo, a protein known to go into inclusion bodies when 
expressed in bacteria.30 The solubilized VEGFno-GyrA-CBD was refolded by 
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Figure 2.26. Preparation of semi-synthetic VEGFuo by EPL. CD VEGFno-
GyrA-CBD is reacted with peptide 5 to produce the monomer form of 
semi-synthetic VEGFuo-Peptide 5, and is purified away from hydrolyzed 
VEGFuo and un-reacted chelator. © The chemically homogenous 
VEGFuo-Peptide 5 can then be refolded into the dimeric and biologically 
active form according to literature procedures. 
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dialysis using the reported procedure,139 and affinity purified over chitin 
beads. An initial concern was the possibility that the eight cysteine residues 
in VEGFuo could cleave the protein away from the GyrA-CBD. Previous 
experiments had shown that appropriately placed cysteines could induce in 
vivo cleavage of the intein domain.20 However, as seen in figure 2.27, no in 
vivo cleavage was detected by SDS-PAGE analysis of the crude cell lysate or 
the affinity purified protein. 
Amersham Health supplied five different 99mTc chelators (Figure 2.28), 
each were bi-functional, containing an N-terminal cysteine (necessary for NCL 
St EPL) and a C-terminal 99mTc chelating moiety. Scheme 2.1 shows the 
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Figure 2.27. Expression and purification of VEGF.,o-GyrA-CBD. VEGFno-
GyrA-CBD is denoted by •, and its expected mass is 40.5 kDa. ® 
denotes where the GyrA-CBD would be if in vivo cleavage were taking 
place. 
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synthetic strategy used to prepare S N 1 4 0 0 - 0 1 . All other chelators were 
synthesized in a similar fashion. 
In preliminary experiments it was shown that all of the molecules 
were stable to the reaction conditions used in NCL and EPL. In particular, 
there was no decomposition of the oxime moieties in the presence of high 













Figure 2.28. ""Tc chelators supplied by Amersham Health. Chelators are 
labeled with their identifying numbers. All of the molecules were stable 
to the reaction conditions used in NCL and EPL conditions. 
Furthermore, they could all ligate to a small Oi-thioester peptide and a 
protein tagged with an intein. 
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Scheme 2.1. Synthesis scheme of SN1400-01. All other chelators provided 
by Amersham Health were synthesized in a similar fashion. 
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Scheme 2.2. Possible decomposition of oxime moieties to a thio-ketal in the 
presence of high concentrations of thiols. This reaction was not observed 
with any of the chelators tested. 
undergo efficient N C L with a model a-thioester peptide, and EPL with a 
model protein (Crk-SH3) (data not shown). 
Initial EPL studies between VEGFno-GyrA-CBD and S N 1400-01 yielded 
the desired ligation product and a side product. Due to hydrolysis of the 
a-thioester during the ligation reaction, the free carboxylic acid of VEGFuo 
was also generated (Figure 2.29 B). The two products could not be 
separated by chromatographic techniques, such as RP-HPLC, ion exchange 
chromatography, and affinity chromatography. U p o n oxidative refolding,30 
three different dimers were produced: the two homo-dimers and the hetero-
dimer (Figure 2.29 C). These three compounds were similarly inseparable by 
chromatography. The generation of a heterogeneous mixture using a one-step 
ligation protocol underlined the need for an alternative tactic for the 
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Figure 2.29. One-step ligation between VEGF„o-GyrA-CBD and SN1400-01. 
(A) Schematic representation of the reaction between VEGFno-GyrA-CBD 
and S N 1400-01. Purified protein and peptide were reacted in 100 m M 
M E S N A and 2 % ethanethiol at p H 7.2 for two days. (B) RP-HPLC (0-
7 3 % B) and ES-MS analysis of the ligation reaction. • denotes the 
ligation product VEGE.o-SN 1400-01 ( O M = 12934.3 + 1.4 Da; E M = 
12930.6 Da) and © denotes the hydrolysis product VEGFuo ( O M = 
12506.1 ± 1.4 Da; E M = 12502.3 Da). (C) RP-HPLC (0-73% B) and 
ES-MS analysis of the oxidative refolding reaction. © © denotes the 
hydrolysis homo-dimer (OM = 24994.0 ± 5.2; E M = 24988.6), •© 
denotes the hetero-dimer (OM = 25417.9 + 2.6; E M = 25416.7), and 
•• denotes the ligation homo-dimer (OM = 25845.2 ± 1.3; E M = 
25845.2). 
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In principle, attachment of an affinity handle to the chelator should 
provide a strategy for purifying the final ligation product away from starting 
material or side-products (e.g. hyrolysis). Therefore a sequential ligation 
approach was developed to incorporate the secondary purification tag (Figure 
2.30). The devised method permits modularity and bypasses the need to 
synthesize the chelators with the affinity handle (possibly a complicated 
synthesis). 
Key to this strategy is the reversible protection of the N-terminal 
cysteine in the affinity tag. In the absence of such protection, cyclization or 
polymerization would occur in the first ligation step (Figure 2.30 CD). To 
conceal the N-terminal cysteine a thiazolidine masking strategy was chosen.140 
The encrypting moiety is removed upon treatment with methoxylamine, 
which is mild, easy and efficient (Figure 2.30). Although the thiazolidine 
masking methodology was well suited for this study, other strategies for the 
concealment of N-terminal cysteines, such as leader sequences that can be 
proteolytically removed47 or chemical protecting groups, such as the 2-
(methylsulfonyl) ethyloxycarbonyl (Msc) group,131 156 are also available, and 
may be appropriate in different contexts. 
While virtually any affinity tag could be used, a 6xHis tag was chosen 
due to its compatibility with denaturants and mildly reducing conditions 
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Figure 2.30. General strategy for tandem ligation of an affinity tag and a 
chelator onto VEGFuo. © The chelator is ligated to an affinity tag 
containing a thiazolidine derivative that serves as a cryptic N-terminal 
cysteine. © After ligation, the cysteine is unmasked by methoxylamine 
treatment, and can then undergo ligation with VEGFno-GyrA-CBD ®. 
The 6xHis tag (peptide 4) was synthesized by Boc SPPS on a 3-
mercaptopropionamide derivatized PEGA resin, as outlined in figure 2.31 CD. 
The N-terminal cysteine of the peptide was incorporated as a thiazolidine 
derivative (thiaproline). The only protecting groups on the peptide were 
dinitrophenyl (DNP) groups on the histidine residues, which allowed for an 
easy and efficient de-protection and cleavage from the resin in a single step 
(overnight treatment with 10% aqueous ethanethiol). Peptide 4 was then 
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Figure 2.31. N C L between peptide 4 and chelator SN1325-01 to produce 
peptide 5. CD The 8 amino acid a-thioester peptide 4 was synthesized 
by Boc SPPS on a 3-mercaptopropionamide derivatized PEGA resin. 
The N-terminal cysteine of the peptide was incorporated as thiaproline. 
De-protection and cleavage from the resin in a single step (overnight 
treatment with 10% aqueous ethanethiol) resulted in the production of 
the OC-thioester Peptide 4. © Peptide 4 was then reacted with SN1325-
01 to produce the protected peptide 5. © After ligation, the cryptic N-
terminal cysteine in peptide 5 was unmasked by the addition of 
methoxvlamine. 
reacted with SN 1325-01 using 100 mM MESNA as the thiol co-factor to 
produce the cysteine protected peptide 5. Unmasking of the cryptic N-
terminal cysteine was accomplished by the addition of methoxylamine.140 
The latter reaction very clean with no side-products. 
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VEGFno-GyrA-CBD was then reacted with purified peptide 5 generating 
the desired ligation product (VEGFuo-Peptide 5) and the free carboxylic acid 
of VEGFuo previously described (see above). However, unlike initial 
experiments, VEGFuo-Peptide 5 could now be purified away from the side-
product. Gel filtration chromatography, under denaturing and mildly 
reducing conditions, first removed un-reacted peptide 5 and thiol cofactors. 
The VEGFuo-Peptide 5 was then purified away from hydrolysis product by Ni-
NTA chromatography. The chemically homogenous VEGFuo-Peptide 5 was 
refolded according to literature protocols,30 and the dimeric product was 
purified by gel filtration chromatography. The final product was analyzed by 
non-reducing SDS-PAGE, RP-HPLC and ES-MS, and confirmed to be the 
homo-dimer of VEGFuo-Peptide 5 (Figure 2.32). Thus addition of the 
secondary affinity tag allowed recovery of the desired ligation product, which 
upon formation of the homo-dimer can be applied to studies in whole 
animals. 
The purified semi-synthetic VEGFuo-Peptide 5 dimer was tested for 
biological activity using an endothelial cell proliferation assay.31 Human 
umbilical vein endothelial cells (HUVEC) were stimulated with either the 
semi-synthetic protein or commercially available VEGFm (R&D Systems). 
Cell proliferation was measured by radiolabeled thymidine, and the EC»s 
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were determined to be 591.6 p M (150.5 - 2325 pM; 95%CI) and 41.1 p M 
(11.9 - 141.7 pM; 95% CI) for VEGF„o-Peptide 5 and VEGFm, respectively 
(Figure 2.33). The ten-fold discrepancy in the obtained EC» values could be 
due to experimental errors (in particular in the concentrations of the stocks), 
or to unforeseen detrimental effects due to the presence of the chelator. 
Nonetheless, VEGFuo-Peptide 5 still binds with high affinity and has maximal 
potency. 
The dimeric and biologically active semi-synthetic VEGFuo-Peptide 5 
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Figure 2.32. Analysis of the VEGF..o-Peptide 5 homo-dimer. (A) Non-
reducing SDS-PAGE analysis. Crude refolding mixture (lane 1), gel 
filtration purification of dimer (lane 2) and reduction of the dimer with 
D T T (lane 3). (B) RP-HPLC (0-73% B) and (C) ES-MS analysis. 
VEGFuo-Peptide 5 homo-dimer is denoted by •• (OM = 27762.9 ± 13.0; 
E M = 27755.4). 
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sample was sent to Amersham Health for "-Tc loading and imaging in whole 
animals. Male C57BL/6 mice were injected sub-cutaneously in their inner 
right thigh with Lewis Lung carcinoma cells. Tumors were allowed to 
develop for 15 days, as previous model studies demonstrated that this time 
point showed the highest level of tumor angiogenesis. VEGFuo-Peptide 5 was 
radiolabeled with "mTc with a low stoichiometry, under a nitrogen 
atmosphere, using a standard protocol.93 Radiolabeled VEGFuo-Peptide5 was 
the injected into tumor bearing animals via their tail vein. Animals were 
killed and dissected at different time points after injection to determine the 
bio-distribution of the semi-synthetic protein. J camera imaging revealed that 
y-radiation localized to the tumor, the urinary tract, spilt urine, liver, and 
kidneys (Figure 2.34). Furthermore, VEGFuo-Peptide 5 was up-taken with 
little gastric intestine (GI) excretion, suggesting that it is binuing to its 
receptors. Displacement experiments with cold VEGF are in progress to 
determine the specificity of VEGFuo-Peptide 5 binding. 
72 
+ VEGFno-Peptide 5 
• hVEGF12i 
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Figure 2.33. Endothelial cell proliferation assay. Incorporation of 
radiolabeled thymidine by H U V E C in response to VEGFno-Peptide 5 (•) 
or VEGF.2. (t). The average count per minute (CPM) of untreated cells 
was 550. The experiments were performed in triplicates. 
Although VEGFno-Peptide 5 localized to the tumor, the negative 
control (hVEGFuo without a chelator) had a similar y emmission distribution 
in mice, however the level of contrast was inferior to that obtained with 
VEGFno-Peptide 5. This observation suggests that V E G F may have an 
intrinsic affinity to ""Tc, or may bind 99mTc through an alternative 
mechanism. O n e such mechanism could involve the two GlyGlyCys 
sequences present within V E G F . These sequences have been reported to 
bind 99nTc within a variety of proteins, under the labeling conditions used.17 
58 129 Varying the ""Tc loading procedures or adding free chelators after 
labeling may help reduce background 99mTc labeling of control VEGFuo. 
Additionally, lengthening the time before imaging could allow better images 
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to be obtained. Such experiments are currently underway at Amersham 
Health. 
It is important to note that in addition to the experiments underway 
at Amersham Health, the modular synthetic strategy developed can also be 
used to sidestep VEGF "mTc labeling issues. For instance, the imaging tag 
can be easily changed to a near-infrared (NIR) fluorophore. NIR 
fluorescence imaging, with the advantage of minimal light absorption by 
hemoglobin and water,147 could by-pass the problems observed, while still 
permitting imaging of angiogenesis. Alternatively, the protein may be 
exchanged to a tumor specific single chain antibodies. The modularity of 
protein, imaging tag, and affinity handle allows for the exploration of a 
number of proteins within a whole animal setting. Future experiments in 








Figure 2.34. Bio-distribution of VEGFuo-Peptide 5 or VEGF..0 control 
observed by y camera imaging at 120 minutes after injection (MAI). (A) 
Image of VEGFno-Peptide 5. (B) Image of VEGFno (no chelator). The 
radiolabeled protein is localized to the tumor, urinary tract, liver and 
kidneys. Note the asymmetry in the image. No y radiation emanates 
from the left thigh (tumor free) of the mouse. 
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C h a p t e r 3: C o n c l u s i o n s a n d F u t u r e Perspectives 
The introduction of unnatural moieties into proteins opens the possibility of 
exploiting the orthogonality and selectivity that chemistry has to offer to study 
polypeptides in their natural environment. This thesis describes the ligation of 
synthetic molecules to target proteins in an intracellular environment, and 
the use of semi-synthetic proteins for whole animal studies. 
Protein semi-synthesis was first explored in a cellular setting. Specifically, a 
methodology was developed to site-specifically modify proteins in living cells. First, 
the ANTP PTD peptide was successfully evaluated as a means of introducing in vitro 
manipulated peptides into cultured eukaryotic cells. It was shown that ANTP 
could translocate up to 70 amino acids, and reliably deliver the L-FLAG 
polypeptide for reaction in vivo. A split intein system was then used to perform 
protein semi-synthesis in vivo. Protein trans-splicing was chosen because the split 
inteins are promiscuous with respect to their flanking sequences,72 are inactive 
when expressed individually,87 " 128 152 associate exclusively with their corresponding 
partner,109 and, specifically for Ssp DnaE, the fragments have high affinity for each 
other.96 Such characteristics allowed for the in vivo ligation of a synthetic FLAG 
tag onto four different cytosolic proteins (GFP, DHFR, GST and YFP), and one 
integral membrane protein (Opsin), thereby demonstrating that, in principle, any 
synthetic molecule - a polypeptide or, minimally, a cysteine derivative bearing any 
chemical moiety - can be ligated to a protein of interest inside living cells. 
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Figure 3.1. Principle of semi-synthetic protein trans-splicing at the N-
terminus of proteins. The L and L components of the semi-synthetic 
protein trans-splicing methodology developed are interchanged to allow 
ligation of chemical moieties at the N-terminus of proteins. 
Furthermore, since the reaction is triggered by the addition of one of the 
components onto the media of cells already expressing the other component, 
temporal control is inherent to the system. Lastly, protein trans-splicing could 
permit ligation at the C- or N-terminus of proteins by interchanging of the split 
intein components (compare Figure 2.5 with Figure 3.1). 
This thesis explored protein trans-splicing as a strategy for the semi-
synthesis of proteins in vivo, however, alternative methodologies could be 
developed. Specifically, NCL and EPL both have characteristics that make 
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them poteintially suitable for semi-synthesis in living cells. N C L is a robust 
reaction that can take place under physiological conditions and in the 
presence of all the functionalities commonly found in proteins, including free 
cysteine sulfhydryls.36 Furthermore, the end product of NCL contains a 
native peptide backbone at the point of ligation.36 EPL, with NCL as its 
last step,103 inherits these same favorable characteristics. Additionally 
modified inteins have been shown to be active in vivo,20 and cells are known 
to tolerate thiols needed as co-factors in both NCL and EPL.65 Preliminary 
experiments have been conducted to test the feasibility of using NCL and 
EPL for the semi-synthesis of protein in living cells (data not shown). 
Figure 3.2 illustrates the general methodology for semi-synthesis of 
proteins in vivo based on NCL. The protein of interest is expressed in 
cultured cells fused at its N-terminus to ubiquitin followed by a cysteine 
(Figure 3.2 CD). Co-translational removal of ubiquitin by ubiquitin hydrolase 
(naturally present in cells) unmasks the N-terminal cysteine, required for 
NCL, within the model protein (Figure 3.2 ©). Then, a synthetic molecule 
with an a-thioester is introduced into the cell (by use of PTDs), whereupon it can 
react with the available N-terminal cysteine (Figure 3.2 ©), resulting in the ligation 
of the probe to the selected protein through a normal peptide bond (Figure 3.2 
©). Key to this methodology will be the correct removal of ubiquitin from the 
protein of interest, and the stability of the resulting protein with an N-terminal 
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cysteine, although, removal of ubiquitin from a polypeptide in mammalian cells has 
been shown to work efficiently in the Muir laboratory (Hofmann and Muir, 
unplublished data). Another issue could be the stability of the synthetic OC-thioester 
within the cell; however the latter issue could be by-passed if the reaction were to 
take place on the cell surface. This strategy would use a minute reactive tag on 
Figure 3.3. Principle of protein semi-synthesis based on E P L in living cells. 
the protein of interest, and therefore have minimal effect on the function and 
localization of the protein. Furthermore, the chemical moiety would not have 
to be synthesized in tandem to an auxiliary polypeptide (e.g. the split intein 
halves) making the system potentially more straightforward to use. 
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Figure 3.3 illustrates the general methodology for semi-synthesis of 
protein in vivo based on EPL. The protein of interest is expressed in 
cultured cells with a modified GyrA intein fused to its C-terminus (Figure 
3.3 ®). Then, a semi-synthetic cysteine derivative is introduced into the cell 
using PTDs (Figure 3.3 ©). The cysteine derivative would attack the Os 
thioester generated by the intein, displacing the intein and attaching itself to 
the protein through a native peptide bond (Figure 3.3 (D). Key to this 
Figure 3.2. Principle of protein semi-synthesis based on N C L in living 
cells. Ubiquitin is in brown and the ubiquitin hydrolase is 
represented as a pair of scissors. When the ubiquitin is removed an 
N-terminal cvsreine is unmasked. 
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methodology will be the specificity of the reaction in terms of the incoming 
peptide, and the minimization of in vivo cleavage. This strategy could by-pass 
some of the solubility and localization problems observed with protein trans-
splicing, as the modified GyrA intein tends to express well. Furthermore, 
and as previously mentioned, the methodology would be more straightforward 
because the chemical moiety would not have to be synthesized in tandem to 
an auxiliary polypeptide (e.g. the split intein halves). It is important to note 
that both NCL and EPL could allow for semi-synthesis on membrane 
proteins, both intra and extra-cellularly. 
Protein semi-synthesis in vivo could become a powerful tool for the 
analysis of proteins within their natural context. Probes, such as 
fluorophores, cross-linkers, unnatural amino acids and other sensors can now 
be added onto cellular proteins, using protein trans-splicing, in order to study 
function. The development of NCL and EPL for use in protein semi-
synthesis in vivo could further increase the permutations for chemically 
modifying proteins, and open new routes for investigating and understanding 
polypeptides. Furthermore, all of the methodologies would have inherited 
temporal control. Table 3.1 presents some possible applications for semi-
synthetic protein trans-splicing in vivo. 
Ultimately, protein semi-synthesis could become an effective instrument 
for whole animal studies. To explore the utility of semi-synthetic proteins as 
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tools for biological questions in the context of whole animals, a modular 
tandem ligation method was developed. This approach combines three 
building blocks: the protein of interest, a second stage affinity tag, and a 
chemical moiety of choice. 










Protein turn-over could be determined independent of 
the half-life of the m R N A using this methodology. 
For example, to determine the turn-over rate of the 
membrane protein Opsin, a construct comprised of 
Opsin-L could be expressed in mammalian cells and 
"pulse" labeled with F L A G tag. The time that Opsin 
takes to completely turn-over would be determined by 
monitoring the disappearance of Opsin-FLAG. 
A sodium ion channel could be labeled with a small 
molecule that chelates Na* ions and, in doing so, 
becomes fluorescent. Such an approach would allow 
direct imaging of Na* transport through a specific 
channel. 
Post-translational modifications of proteins play a 
crucial role in cell biology. A common modification 
involves the addition or removal of phosphate 
groups. This methodology could allow the addition 
of non-hydrolysable phosphate groups to proteins of 




these modifications. For example Smad-2, known to 
have two phosphorylation sites at its C-terminus, 
could be semi-synthetically modified to produce a 
unnatural version of Smad-2 containing two non-
hydrolysable phosphate groups. This would allow to 
study the effects of a constitutevily active Smad-2. 
The breakage of a bond that takes place in protein 
splicing can be taken advantage of to create a site-
specific proteolysis tool. Such a tool would allow to 
temporally control the separation of two fused poly-
peptides inside the cell. For example, a kinase 
inhibitor peptide could be cloned onto the C-
terminus a kinase of interest (PKA), with L present 
in between the two (PKA-L-lnhibitor). W h e n this 
construct would be expressed in mammalian cells the 
P K A would be inactive due to the presence of the 
peptide inhibitor. Upon addition of L, semi-
synthetic protein trans-splicing would remove the 
inhibition and P K A could become active. Such work 
in underway in the laboratory. 
The first and last units are dictated by the experiment at hand, but 
the intervening unit can be varied to fit circumstantial needs, such as the 
conditions for purification. VEGF was used as a model protein in an 
attempt to develop a tumor-imaging agent. A ""Tc chelator was ligated to 
the C-terminus of VEGFuo with a 6xHis second stage affinity handle, which 
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allowed recovery of a chemically homogenous monomeric protein. The 
refolded and dimeric semi-synthetic VEGFno-Peptide 5 was shown to be 
biologically active and able to target tumors in mice. 
This thesis has developed methodologies for the application of 
synthetic protein chemistry to in vivo systems. Effective approaches have been 
established to study proteins in both cellular and whole animal contexts in 
an attempt to provide tools to address the question of lifes' regulation by 
proteins. 
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Chapter 4: Materials a n d M e t h o d s . 
General Methods. 
All amino acid derivatives and resins were purchased from 
NovaBiochem (San Diego, CA), Peninsula Laboratories (Belmont, CA) and 
Bachem (Torrance, CA). All other chemical reagents were purchased from 
Sigma-Aldrich (Milwaukee, WI) or Fisher (Chicago, IL). Restriction enzymes 
were purchased from New England Biolabs (Boston, MA). Cell culture 
reagents were purchased from Gibco BRL. Fugene transfection reagent was 
bought from Boehringer Mannheim. Analytical gradient HPLC was 
performed on a Hewlett-Packard 1100 series instrument with detection at 214 
and 280 nm. Analytical HPLC was performed on a Vydac C18 column (5 
micron, 4.6 x 150 mm) at a flow rate of 1 mL/min. Preparative HPLC 
was routinely performed on a Waters DeltaPrep 4000 C18 column (15-20 
micron, 50x250 mm) at a flow rate of 30 mL/min. All runs used linear 
gradients of 0.1% aqueous TFA (solvent A) vs. 90% acetonitrile plus 0.1% 
TFA (solvent B). Mass spectrometric analysis was routinely applied to all 
synthetic peptides and components of reaction mixtures. Electrospray mass 
spectrometry (ESMS) was performed on a Sciex APL100 single quadrupole 
electrospray mass spectrometer. Antibodies used were from Zymed, Sigma 
and Clontech. Primers were ordered from IDT or Invitrogen. HeLa, MCF-
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7 and C H O cells were a generous gift from the Simon laboratory. H U V E C 
cells and their media were purchased from Cell Applications. 
Peptide Synthesis. 
All peptides were synthesized on a 0.5 mmol scale on a 4-
methylbenzhydrylamine (MBHA) resin according to the in-situ 
neutralization/HBTU activation protocol for Boc SPPS, unless otherwise 
noted.124 Following chain assembly, global de-protection and cleavage from 
the support was achieved by treatment with HF containing 4% v/v p-cresol, 
for 1 hour at 0°C. Following removal of the HF, the crude peptide 
products were precipitated and washed with anhydrous cold EtzO before 




The peptide was made by NCL between amino acids 1-39 (Peptide a -
synthesized with an C-terminal CMhioester) and amino acids 40-70 (Peptide b 
- synthesized with an N-terminal cysteine). 
The crude peptide a was purified by preparative HPLC using a linear 
gradient of 30-40% B over 60 minutes. The purified peptide was 
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characterized as the desired product by E S M S [observed mass (OM) = 4300.1 
±1.2 Da; expected mass (average isotopic mass)(EM) = 4301.5 Da]. 
Rh was attached to the e-NHa group of Lys30 of peptide b using an 
orthogonal (Fmoc/Boc) protection strategy. The crude peptide b was purified 
by preparative HPLC using a linear gradient of 20-40% B over 60 minutes. 
The purified peptide was characterized as the desired product by ESMS [OM 
= 4170.5 ± 1.4 Da; EM = 4172.6 Da]. 
Peptide a (10 mgr; 2.3 (Imols) was mixed with peptide b (5 mgr; 1.2 
Jlmols) in 50 mM Tris/HCl pH 7.5 with 100 mM MESNA and 20% (v/v) 
acetonitrile. The reaction was allowed to take place overnight at room 
temperature, and then was quenched with acid. The crude mixture was 
reduced with TCEP and peptide 1 was purified by preparative HPLC using a 
linear gradient of 35-45% B over 60 minutes. 11 mgr of peptide 1 was 
obtained. The purified peptide was characterized as the desired product by 
ESMS [OM = 8366.3 ± Ll Da; EM = 8366.9 Da]. 
Peptide 2 (L-FLAG): 
H-MVKVIGRRSLGVQRIFDIGLPQDHNFLI^NGAIAAN 
CFNDYKDDDDKG-NH, 
The crude peptide was purified by preparative HPLC using a linear 
gradient of 25-45% B over 60 minutes. 41.7 mgr of peptide 2 was 
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obtained. The purified peptide was characterized as the desired product (L 




Rh was attached to the eNIHz group of Lys47 using an orthogonal 
(Fmoc/Boc) protection strategy. The crude peptide was purified by 
preparative HPLC using a linear gradient of 30-50% B over 60 minutes. 
10.3 mgr of Ic-FLAG-Rh was obtained. The purified peptide was 
characterized as the desired product (Ic-FLAG-Rh) by ESMS [OM = 5732 ± 




The resin from the Ic-FLAG synthesis was used to couple an extra N-
acetylated Cys residue protected on the thiol group with a 9-fluoronylmethyl 
(Fm) group. The crude peptide was purified by preparative HPLC using a 
linear gradient of 35-55% B over 60 minutes. The purified peptide was 
characterized as Ac-Cys(Fm)-Ic-FLAG by ESMS [OM = 5687.3 ± 1.7 Da; EM 
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= 5687.7 Da]. The peptide was then alkylated in solution by resuspending 
it in 5 mL of DMF with 5% DIEA with 10 mM iodoacetamide. The 
reaction was allowed to proceed for 15 minutes at room temperature and 
500 JlL of IM DTT was then added to quench the un-reacted 
iodoacetamide. After 5 minutes at room temperature, piperidine was added 
to a final concentration of 20% to deprotect the N-terminal Cys. The 
reaction was then quenched with 5 volumes of 20% buffer B and was 
purified by preparative HPLC using a linear gradient of 0-70% B over 60 
minutes. 3.2 mgr of L(S-R)-FLAG was obtained. The purified peptide was 
characterized as the desired product (L(S-R)-FLAG) by ESMS [OM = 5566.2 
± 1.7 Da; EM = 5567.6 Da]. 
A N T P : 
H-C(NPyS)RQIKIWFNNRRMKWKKKG-NH2 
The crude peptide was purified by preparative HPLC using a linear 
gradient of 35-45% B over 60 minutes. 74.4 mgr of ANTP was obtained. 
The purified peptide was characterized as the desired product (ANTP) by 




R h was attached to the £-NH; group of Lys16 using an orthogonal 
(Fmoc/Boc) protection strategy. The crude peptide was purified by 
preparative HPLC using a linear gradient of 20-40% B over 60 minutes. 
6.6 mgr of Rh-ANTP was obtained. The purified peptide was characterized 




Rh was attached to the e-NHi group of Lys5 using an orthogonal 
(Fmoc/Boc) protection strategy. The crude peptide was purified by 
preparative HPLC using a linear gradient of 10-30% B over 60 minutes. 13 
mgr of peptide 3 was obtained. The purified peptide was characterized as 
the desired product (peptide 3) by ESMS [OM = 987.9 ± 0.3 Da; EM = 
988.2 Da]. 
Coupling of the L-probe to the P T D . 
Ic-FLAG, Ic-FLAG-Rh or L(SR)-FLAG was dissolved together with 
ANTP or Rh-ANTP in degassed 50 mM Tris/HCl buffer pH 7.5 to a 
concentration of 1 mM in each. The peptides were allowed to react for 5 
minutes at room temperature and the reaction was then quenched with 10 
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volumes of buffer A and purified over preparative H P L C using a liner 
gradient of 20-40% B over 60 minutes. The purified peptides were 
characterized as the desired products by ESMS [ANTP-S-S-Ic-FLAG, OM = 
7895.8 ± 0.5 Da, EM = 7895.5 Da; ANTP-S-S-L-FLAG-Rh, OM = 8309.8 ± 
1.5 Da, EM = 8309.8 Da; Rh-ANTP-S-S-Ic-FLAG, OM = 8267.2 ± 2.5 Da, 




The peptide was synthesized on a S-propionamide derivatized PEGA 
resin on a 0.15 mmol scale. The peptide was simultaneously cleaved from 
the resin and de-protected by overnight stirring in 10% aqueous ethanethiol. 
The ethanethiol was then removed in vacuo, and the resulting yellow solution 
was lyophilized. The crude peptide was purified by preparative HPLC using 
a linear gradient of 10-25% B over 60 minutes. The purified peptide was 
characterized as the desired product (Peptide 4) by ESMS [OM = 1057 ±0.1 




SN1325-01 (12 mgr; 0.0287 mmol) and peptide 4 (47 mgr; 0.0431) 
were dissolved in 15 mL of buffer containing 200 mM sodium phosphate, 
200 mM NaCl, 0.1% Triton X-100, 100 mM MESNA pH 7.2. The 
reaction was allowed to proceed for 3 days at room temperature. 5 mL of 
IN NaOH was added to bring the pH to 12.5 and hydrolyze remaining CL-
thioesters. After 3 minutes, 7.5 mL of IM HC1 were added to bring the 
pH to 4.5. Methoxylamine-HCl (1.127 grams) was then added and the 
deprotection reaction was allowed to take place overnight at room 
temperature. The ligation product was purified by preparative HPLC using a 
linear gradient of 10-25% B over 60 minutes. The purified peptide was 
characterized as the desired product (Peptide 4) by ESMS [OM = 1400.3 ± 
0.5 Da; EM = 1401.4 Da]. 
Expression plasmids. 
All plasmids were constructed using standard molecular biology 
techniques,123 and they were sequenced to verify correct coding. 
pGFP-L: A PCR fragment amplified with IGpr63 and IGpr64, encoding L 
with 5 N-terminal extein residues (KFAEY) (using the plasmid reported in 151 
as the template) was inserted at the C-terminus of GFP on pEGFPNl 
(Clontech) between the BsRG I and Not I restriction sites. 
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p6xHis-GFP-L: A P C R fragment amplified with IGprl02 and IGprl03, 
encoding 6xhisGFP-L (using pGFP-L as the template) was inserted into 
pETlld (Novagene) between the Nhe I and BamH I restriction sites. 
pGFP-L(Ala250): Cys250 of pGFP-L was mutated to Ala using Quickchange 
Site-Directed Mutagenesis Kit (Stratagene) with IGprlll and IGprll2. 
pNl: The sequence of EGFP was removed from pEGFPNl by digestion 
with Bsp 120 I and Not I, and the backbone was then re-ligated to make 
pNl. 
pGST-L: A PCR fragment amplified with IGpr81 and IGpr83, encoding 
GST (using pGEX 2T (Amersham Bioscience) as the template) was inserted 
into pNl between the Bgl II and EcoR I restriction sites. A PCR 
fragment amplified with IGpr84 and IGpr85, encoding L with 5 N-terminal 
extein, was then inserted at the C-terminus of GST between the Hind III 
and EcoR I restriction sites. 
p D H F R - L : A P C R fragment amplified with IGpr86 and IGpr87, encoding 
6xhisDHFR (using pMT490 as template) was inserted into pNl between the 
Bgl II and Nhe I restriction sites. A PCR fragment amplified with IGpr90 
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and IGpr91, encoding L with 5 N-terminal extein, was then inserted at the 
C-terminus of 6xhisDHFR between the Xma I and Bgl II restriction sites. 
pYFP-L-CFP: A PCR fragment amplified with IGpr99 and IGprlOl, 
encoding L with 5 N-terminal extein, was inserted at the N-terminus of CFP 
on pCFP (Clontech) between the EcoR I and BamH I restriction sites. The 
resulting intermediate plasmid was digested with BsiW I and Not I to 
removed the L-CFP fragment and inserted it onto the C-terminus of YFP on 
pYFPNl (Clontech) between the BsRG I and Not I restriction sites. 
pOpsin-GFP-L: A PCR fragment amplified with IGpr75 and IGpr92, 
encoding Opsin, was inserted at the N-terminus of GFP on pEGFPNl 
between the Sac I and EcoR I restriction sites. Then a PCR fragment 
amplified with IGpr63 and IGpr64, encoding L with 5 N-terminal extein 
residues (KFAEY) (using the plasmid reported in 151 as the template) was 
inserted at the C-terminus of Opsin-GFP between the BsRG I and Not I 
restriction sites. 
pTnfR-GFP: A P C R fragment amplified with IGpr29 and IGpr30, encoding 
the trans-membrane domain of TnfR, was inserted at the N-terminus of GFP 
on pEGFPNl between the Hind III and EcoR I restriction sites. 
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pTnfR-GFP-L: A P C R fragment amplified with IGpr63 and IGpr64, 
encoding L with 5 N-terminal extein residues (KFAEY) (using the plasmid 
reported in 151 as the template) was inserted at the C-terminus of TnfR-GFP 
between the BsRG I and Not I restriction sites. 
pL-GyrA-CBD: A P C R fragment amplified with IGpr65 and IGpr66, 
encoding L with 3 C-terminal extein residues (CFN) (using the plasmid 
reported in 151 as template) was inserted at the N-terminus of Gyrase A on 
pTXBl (NEB) between the Nde I and Sap I restriction sites. 
pVEGFuo-GyrA-CBD: A PCR fragment amplified with RFpr09 and RFprlO, 
encoding VEGFuo with four extra C-terminal amino acids (AAAAGG) (using 
a hVEGF coding plasmid from Research Genetics as template) was inserted 
at the N-terminus of Gyrase A on pTXBl (NEB) between the Nde I and 






!Gprl02: C T A G C T A G C A T G C A C C A C C A C C A C C A C C A C G G G G T G A G C A 
AGGGCGAGG 
IGprl03: CGGGATCCGCGGCCGCTTATTTAATTGTCCCAGCGTC 
IGprl 1 li GCAAGTTTGCGGAATATGCCCTCAGTTTTGGCACC 


























Bacterial expression and purification. 
6xHisGFP-L: E. coli BL21 (DE3) cells (Invitrogen) were transformed with 
p6xhisGFP-L. Expression was carried out in LB media at 37°C. Cells were 
grown to an OD5«o™ of 0.8, and protein expression was induced by addition 
of isopropyl-P-D-thiogalactopyranoside (IPTG) to a final concentration of 1 
mM. After 5 hours the cells were harvested by centrifugation. The cell 
pellet was resuspended in bacterial lysis buffer (100 mM Tris/HCl pH 7.5, 
500 mM NaCl, 20 mM fi-mercaptoethanol and protease inhibitors (Roche)) 
and disrupted using a french press. Insoluble material was pelleted by 
centrifugation and the supernatant was added onto Ni-NTA agarose beads 
(Novagen) previously equilibrated in lysis buffer. After overnight incubation 
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at 4°C the beads were washed twice with lysis buffer and the protein was 
eluded with lysis buffer containing 500 mM imidazole. The eluant was 
dialyzed against storage buffer (100 mM Tris/HCl pH 7.5, 500 mM NaCl, 1 
mM EDTA and 10 mM DTT), and stored at 4°C. 
Ic-GyrA-CBD: E. coli BL21 (DE3) cells were transformed with pIc-GyrA-CBD. 
Expression was carried out in LB media at 25 °C. Cells were grown to an 
OD59o»„ of 0.8, and protein expression was induced addition of IPTG to a 
final concentration of 1 mM. After 5 hours the cells were harvested by 
centrifugation. The cell pellet was resuspended in bacterial lysis buffer (50 
mM Tris/HCl pH 7.5, 200 mM NaCl, 5% glycerol, 0.1 mM EDTA and 
protease inhibitors) and disrupted using a french press. Insoluble material 
was pelleted by centrifugation and the supernatant was added onto chitin 
beads (NEB) previously equilibrated in lysis buffer. After overnight 
incubation at 4°C the beads were washed twice with lysis buffer and stored 
at 4°C. 
VEGFu^GyrA-CBD: E. coli BL21 (DE3) cells were transformed with pVEGF™-
GyrA-CBD. Expression was carried out in LB media at 37 "C. Cells were 
grown to an ODsw™ of 0.8, and protein expression was induced by addition 
of IPTG to a final concentration of 1 mM. After 5 hours the cells were 
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harvested by centrifugation. The cell pellet was resuspended in bacterial lysis 
buffer (25 mM sodium phosphate pH 7.0, 250 mM NaCl, 0.1 mM EDTA, 
5% glycerol, and protease inhibitors) and disrupted using a french press. 
Insoluble material was pelleted by centrifugation. The pellet was washed 
with 2 M urea in lysis buffer, and insoluble material was pelleted by 
centrifugation. The pellet was resuspended in 200 mM sodium phosphate pH 
7.2 and 8 M urea and insoluble material removed by centrifugation. The 
supernatant was dialyzed for 24 hours against 50 mM Tris/HCl pH 7.5, 200 
mM NaCl, 1 mM EDTA and 0.1% Triton X-100 in a Spectra Pore dialysis 
bag with a 10,000 Da molecular weight cutoff. The dialyzed solution was 
centrifuged to remove insoluble components, and was then loaded onto a 
chitin column (NEB) previously equilibrated with 200 mM sodium phosphate 
pH 7.2, 200 mM NaCl, 0.1% triton X-100. After overnight incubation at 
4°C, the column was washed with buffer containing 200 mM sodium 
phosphate pH 7.2, 200 mM NaCl, 0.1% triton X-100 and stored at 4°C. 
In vitro reactions. 
Semi-synthetic protein trans-splicing: The bacterially expressed 6xHisGFP-L in 
100 mM Tris/HCl pH 7.5, 500 mM NaCl, 1 mM EDTA and 10 mM DTT 
was added to Ic-FLAG to obtain a final concentration of the peptide of 100 
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rltM. The mixture was allowed to react at room temperature for 5 hours and 
was then analyzed by SDS-PAGE gel (12%) and by an anti-FLAG blot. 
EPL of Ic-GyrA-CBD with peptide 3: An aliquot of the bead slurry containing 
immobilized Ic-GyrA-CBD was incubated overnight with 1 mL of peptide 3 
(1 mM) in PBS with 100 mM MESNA at room temperature. The reaction 
was monitored by SDS-PAGE. The supernatant was removed and the beads 
were washed with 8 M urea. The eluant was injected into the analytical 
HPLC to analyze the reaction, and to confirm product formation by ESMS 
[Ic-Peptide 3: OM = 5298.3 ± 2.0 Da; EM = 5299.7 Da]. 
E P L between VEGFuo-GyrA-CBD and SN1400-01: VEGFuo-GyrA-CBD 
chitin beads (30 mL) were treated in 50 mL ligation buffer (200 mM 
sodium phosphate pH 7.2, 200 mM NaCl, 0.1% triton X-100) with 100 mM 
MESNA and 2% (v/v) ethanethiol in the presence of SN 1400-01 peptide (10 
mgr; 22.4 .Umols) and rocked for 2 days at room temperature. The 
column was drained, washed with ligation buffer, and the ligation product 
was eluted by washing the column with a buffer containing 8 M urea, 200 
mM sodium phosphate, 20 mM DTT, pH 7.2. The urea solution was then 
dialyzed against 20 mM Tris/HCl pH 8.0, 200 mM NaCl. A mixture of 
the ligation products, VEGFuo-SN 1400-01 and VEGFuo (hydrolysis product) 
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were purified by preparative H P L C using a linear gradient of 32-47% B over 
60 minutes. The purified proteins were characterized by ESMS [VEGFuo-
SN1400-01 OM = 12934.3 ± 1.4 Da; EM = 12930.6 Da and VEGFuo OM = 
12506.1 ± 1.4 Da; EM = 12502.3 Da]. 
EPL between VEGF„o-GyrA-CBD and peptide 5: VEGFuo-GyrA-CBD chitin 
beads were treated with 2% ethanethiol in ligation buffer for 2 days. The 
VEGFuo a-thioester was eluted by overnight treatment with 8 M Urea, 200 
mM sodium phosphate, pH 7.2 with 2% ethanethiol, and purified by 
preparative HPLC using a linear gradient of 40-55% B over 60 minutes. 
VEGFuo ethyl thioester (5 mgr; 0.4 Jlmols) were then dissolved in 6 M 
guanidine, 200 mM sodium phosphate pH 7.2, 200 mM sodium chloride, 
2% ethanethiol and 100 mM MESNA in the presence of peptide 5 (5 mgr; 
11.9 Jlmols). The reaction was allowed to take place overnight at room 
temperature. The ligation mixture was purified by size-exclusion 
chromatography on a Zorbax GF-450 column using a flow rate of 5 mL/min 
and a running buffer containing 6 M guanidine, 200 mM NaCl, 200 mM 
sodium phosphate pH 7.2, 20 mM 2-mercaptoethanol, and 0.1 mg/mL BSA. 
The fraction containing VEGFuo-Peptide 5 was then further purified by Ni-
NTA chromatography over a Hi-Trap Affinity column (Pharmacia), on a 
Pharmacia FPLC system, at a flow rate of 5 mL/min using 6 M guanidine, 
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200 m M sodium phosphate, 500 m M NaCl, 20 m M 2-mercaptoethanol p H 
7.4 as loading buffer, and an identical buffer with 500 mM imidazole as the 
eluting buffer. Purified VEGFuo-Peptide 5 was oxidatively refolded according 
to literature protocols30 by dialyzing against 20 mM Tris/HCl pH 8.0, 400 
mM sodium chloride, 1 mM cysteine. Dimeric VEGFuo-Peptide 5 was then 
separated from monomeric and other oligomeric species by gel filtration 
chromatography on a Zorbax GF-250 column using a flow rate of 5 mL/min 
and PBS as the running buffer. 
Fluorescence Microscopy. 
Live cell imaging: HeLa were grown in DMEM+ 10% fetal bovine serum 
(FBS) media at 37 °C with 5% COz in a microscopy chamber. Peptide 1 
was added to a final concentration of 1 nM. After 30 minutes incubation, 
the cells were washed with Hanks' balanced salt solution (HBSS) and imaged 
live by fluorescence microscopy on an Axiovert 200 M inverted microscope. 
A TxRd filter (Chroma) was used to image the Rh signal, and the data was 
analyzed using MetaMorph (Universal Imaging). 
Fixed cell imaging for peptide localization: HeLa cells were grown in DMEM 
+ 10% FBS media at 37 °C with 5% COz, on #1.5 glass cover slips (Fisher). 
Before adding the peptides (ANTP-S-S-Ic-FLAG-Rh or Rh-ANTP-S-S-Ic-FLAG), 
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the cells were washed twice with PBS, and then fresh media was added 
containing the peptides at a concentration of 2 nM. After 30 minutes of 
incubation, the cells were fixed with 3.7% formaldehyde, followed by BSA 
blocking and nucleic acid staining with Hoechst. The cover slips were 
inverted onto a glass slide and sealed with nail polish before fluorescence 
microscopy analysis. A DAPI or a TxRd filter (Chroma) was used to 
visualize the signals from Hoechst or Rh, respectively. The data was 
analyzed using MetaMorph. 
Fixed cell imaging for protein localization: HeLa or MCF-7 cells were grown 
in DMEM + 10% FBS media at 37 °C with 5% C02, on #1.5 glass cover 
slips, and transiently transfected with the desired plasmids using Fugene. 
After 24 hours of expression the cells were washed twice with PBS and fixed 
with 3.7% formaldehyde, followed by BSA blocking and nucleic acid staining 
with Hoechst. The cover slips were inverted onto a glass slide and sealed 
with nail polish before fluorescence microscopy analysis. A FITC filter 
(Chroma) was used to image the GFP signal, and the data was analyzed 
using MetaMorph. 
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Western Analysis of pGFP-L . 
CHO cells, grown in F12-HAM + 10% FBS media at 37 °C with 5% 
CO2, were transiently transfected with pGFP-L using Fugene. After 24 hours 
of expression the cells were washed twice with PBS and harvested. The cell 
pellet was resuspended in SDS sample buffer and loaded onto an SDS-PAGE 
gel (12%) for blotting against GFP. 
Semisynthetic protein trans-splicing. 
10 cm plates of CHO cells were transfected with a mammalian vector 
based on pEGFP-Nl (Clontech) encoding the L fusion protein (GFP-L, GFP-
L(Ala2»), GST-L, DHFR-L, YFP-L-CFP or Opsin-GFP-L). After 24 hours of 
transient expression, the cells were washed twice with 10 mL of PBS and 
fresh media (2.5 mL) containing 0.5% DMSO or 0.5% DMSO with the 
peptide (ANTP-S-S-Ic-FLAG or ANTP-S-S-L(SR)-FLAG) to a final concentration 
of 100 (iM was added. The cells were then incubated for three hours, 
washed twice with 10 mL of PBS and harvested. The cell pellet was 
resuspended in 1 mL of lysis buffer: PBS containing 1% (w/v) 
docecylmaltoside (DM), 10 mM iodoacetamide, 2 mM N-ethyl-maleamide and 
protease inhibitors (Roche). All subsequent manipulations were performed at 
4°C. Lysis was carried out for 1 hour after which insoluble material was 
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removed by micro-centrifugation at 16,000g for 30 minutes. The supernatant 
was pre-cleared for immuno-precipitation by incubation with 50 [iL of 
Protein-A immobilized on sepharose CL-4B (Sigma) or mouse IgG agarose 
(Sigma) for 1 hour. The beads were then removed by micro-centrifugation 
at 16,000g for 5 minutes and the supernatant added onto 50 JlL of anti-
FLAG-Protein-A sepharose, anti-GFP-Protein-A sepharose or anti-FLAG M2-
agarose affinity gel (Sigma) pre-blocked with bovine albumin (BSA). Immuno-
precipitation was allowed to take place overnight and the beads were then 
washed three times for 5 minutes with 1 mL of PBS before being 
resuspended in SDS sample buffer for analysis by western blotting. 
Endothelial Cell Proliferation Assay. 
A plate of HUVEC primary cultures (Cell Applications) was grown to 
confluence over 4 days using endothelial cell growth media (Cell 
Applications). VEGF samples were reconstituted by dissolving or diluting the 
samples to generate a 10 \lg/mL stock in PBS with 1 mg/mL BSA (Sigma). 
These stocks were diluted into assay medium (medium 199 with 10 mM 
HEPES, 10% FBS, 100 units/mL penicillin, 100 |lg/mL streptomycin) at 
various concentrations, and 75 \lL of each dilution was plated in triplicate 
in a 96-well plate. 50 |lL of a solution of IO5 cells/mL in assay medium 
was then added to each well. The cells were allowed to grow for 48 hours 
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under 5 % C O , at 37"C degrees. 10 |lL of a 50 (iCi/mL stock of 'H-
Thymidine (NEN) was added to each well, and the cells were allowed to 
grow for an additional 24 hours. The cells were dissociated with trypsin, 
and counted in a scintillation counter. The data were fitted to a sigmoidal 
dose response curve using Prism 3.0 (Graphpad Software), using the following 
equation: 
E = Basal+E™*~Basal/ 
Cj Dasat + ^^0(LogEC50-Log[A?« ) 
where E denotes effect, [A] the VEGF concentration, nH the midpoint 
slope, EC50 the midpoint location parameter, and E™. and Basal the 
upper and lower asymptotes, respectively. 
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A c a d e m i c Course W o r k 
Transmission genetics. 
Introduction to protein function. 
Development of the nervous system. 
Mammalian genetics. 
Protein folding and structure prediction. 
Gene expression. 
Advanced organic chemistry. 
Laboratory Rotations 
September 1997 - December 1997: Dr. Ali Hemmati Brivalauo 
January 1998 - April 1998: Dr. John Kuryain 
May 1998 - March 1999: Dr. Titia de Lange 
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